

Disclaimer

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at info@mini-sentinel.org.

Overview

Request Description FDA requested use of Modular Program #3 to investigate incident use of testosterone products among members with pre-existing inclusions indicative of testosterone use (Appendix A) , as well as members with no inclusion/exclusion condition criteria. In total, 36 scenarios were examined in this report with differing inclusion criteria and exposures of interest. This request required three runs of MP3. No event was queried. The time window for the request was January 1, 2007 to May 31, 2013. The package was distributed to 18 Data Partners on March 17, 2014. This report includes data from 18 Data Partners. Please see the Specifications tab for more details on each scenario.

Request ID Specifications to09y05_mpr_wp20_v01 (Report 1 of 1)
Program parameter inputs and scenarios

Glossary List of Terms found in this Report and their Definitions

Table 1 Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, Amount Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 100,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Drug Product and Inclusion Criteria

Table 2 Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, Amount Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 100,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Drug Product, Inclusion Criteria, and Age Group

Table 3 Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, Amount Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 100,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Drug Product, Inclusion Criteria, and Sex

Table 4 Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, Amount Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 100,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Drug Product, Inclusion Criteria, and Year

Table 5 Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, Amount Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 100,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Drug Product, Inclusion Criteria, Sex, and Age Group

Appendix A ICD-9 Diagnosis Codes for Pre-existing Condition Criteria Included in this Request

Notes: Please contact the Mini-Sentinel Operations Center (MSOC_Requests@harvardpilgrim.org) for questions and to provide comments/suggestions for future enhancements to this document.

Specifications for Query ID to09y05_mpr_wp20_v01

Modular Program #3 was used to investigate incident use of testosterone products among members with a pre-existing inclusions indicative of testosterone use (see Appendix A) (scenarios 1-

Coverage Requirement Drug and Medical Coverage
Query Period January 1, 2007 to May 31, 2013
Enrollment Gap 45 Days
Enrollment Days 183
Minimum Days Supplied and Minimum Episode Duration 0
Age Stratifications 0-39, 40-64, 65-74, 75+

Scenario	Drug/Exposure		Condition Criteria							Event/Outcome				
	Incident exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Care Setting PDX	Tx Episode Truncation Indicator	Conditions	Include/Exclude	Lookback Start	Lookback End	Care Setting PDX	Event/Outcome
1	Androgel	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
2	Testosterone cypionate	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
3	Axiron	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
4	Fortesta	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
5	Testim	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
6	Striant	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
7	Testosterone transdermal other	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
8	Testopel	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
9	Methyltestosterone oral	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
10	testosterone intramuscular other	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
11	Injection, testosterone cypionate, up to 100 mg (J1070)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None

Scenario	Drug/Exposure								Condition Criteria				Event/Outcome	
	Incident exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Care Setting PDX	Tx Episode Truncation Indicator	Conditions	Include/Exclude	Lookback Start	Lookback End	Care Setting PDX	Event/Outcome
12	Injection, testosterone cypionate, 1 cc, 200 mg (J1080)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
13	Injection, testosterone suspension, up to 50 mg (J3140)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
14	Injection, testosterone enanthate, up to 100 mg (J3120)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
15	Injection, testosterone enanthate, up to 200 mg (J3130)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
16	Injection, testosterone propionate, up to 100 mg (J3150)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
17	Testosterone pellet, 75mg (S0189)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
18	All testosterone use (NDC and procedure codes)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	All testosterone indications	Include	-183	-1	Any	None
19	Androgel	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
20	Testosterone cypionate	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
21	Axiron	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
22	Fortesta	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
23	Testim	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
24	Striant	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
25	Testosterone transdermal other	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
26	Testopel	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
27	Methyltestosterone oral	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
28	Testosterone intramuscular other	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
29	Injection, testosterone cypionate, up to 100 mg (J1070)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
30	Injection, testosterone cypionate, 1 cc, 200 mg (J1080)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None

Scenario	Drug/Exposure							Condition Criteria					Event/Outcome	
	Incident exposure	Incident w/ respect to:	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Care Setting PDX	Tx Episode Truncation Indicator	Conditions	Include/Exclude	Lookback Start	Lookback End	Care Setting PDX	Event/Outcome
31	Injection, testosterone suspension, up to 50 mg (J3140)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
32	Injection, testosterone enanthate, up to 100 mg (J3120)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
33	Injection, testosterone enanthate, up to 200 mg (J3130)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
34	Injection, testosterone propionate, up to 100 mg (J3150)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
35	Testosterone pellet, 75mg (S0189)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None
36	All testosterone use (NDC and procedure codes)	All testosterone use (NDC and procedure codes)	183	01 (SING)	0	0	Any	No	None	n/a	n/a	n/a	n/a	None

* If Yes, then treatment episodes are truncated when encountering a claim from the incident list.

NDC codes checked against First Data Bank's "National Drug Data File (NDDF®) Plus"

ICD-9-CM diagnosis and procedure codes checked against "Ingenix 2012 ICD-9-CM Data File" provided by OptumInsight

HCPCS codes checked against "Optum 2012 HCPCS Level II Data File" provided by OptumInsight

CPT codes checked against "Optum 2012 Current Procedure Codes & Relative Values Data File" provided by OptumInsight

Glossary of Terms in Modular Program 3*

- Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the "RxAmt"
- Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
- Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other
- Cohort Definition (drug/exposure)**- Indicates how the cohort will be defined: (1) 01: Cohort includes only the first valid incident treatment episode during the query period; (2) 02: Cohort includes all valid incident treatment episodes during the query period; (3) 03: Cohort includes all valid incident treatment episodes during the query period until an event occurs
- Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.
- Years at Risk** - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.
- Eligible Members** - Number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.
- Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled"
- Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same
- Event Deduplication** - specifies how events are counted by the MP algorithm: A value of 0 counts all occurrences of an event group code of interest; a value of 1 de-duplicates occurrences of the same event code on the same day (i.e., de-duplicates at the exact match code level); and a value of 2 de-duplicates occurrences of the same event group code on the same day (e.g., de-duplicates at the GROUP level).
- Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode.
- Lookback Period (pre-existing condition)** - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).
- Member-Years** - sum of all days of enrollment with medical and drug coverage** in the query period preceded by an exposure washout period all divided by 365.23.
- Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered
- Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered
- New Episodes** - new treatment episodes; length of episode is determined by days supplied in one dispensing (or consecutive dispensings
- New Episodes with Events** - number of unique episodes during which at least one incident event occurs. Each episode may only be counted
- New Users** - number of members with incident exposure during the query period. Member must have no evidence of exposure (s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.
- Number of Events** - total number of incident events. An individual or a treatment episode can have more than one incident event provided that the incident event meets the event incidence criteria.
- Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. YES will only consider diagnoses flagged as Principal
- Query Period** - period in which the modular program looks for exposures and outcomes of interest.
- Treatment Episode Truncation Indicator** - indicates whether observation of the incident query code during follow-up requires truncation of valid treatment episodes. A value of Y indicates that the treatment episodes should be truncated at the first occurrence of an incident query code. A value of N indicates that the treatment episodes should not be truncated at the occurrence of the incident query code.
- Washout Period (drug/exposure)**** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
- Washout Period (event/outcome)**** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

*all terms may not be used in this report

**incident treatment episodes must be incident to both the exposure and the event

Table 1. Summary of Incident Testosterone use in the MSDD between January 1, 2007 and May 31, 2013, by Testosterone Product and Pre-existing Conditions

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
All Testosterone Products												
<i>With testosterone indications</i>	331,302	331,302	470,256	13,322,369	44,591,984	36,123.2	17,491,834	12,591,409.0	1,894.04	40.21	1.42	28.33
<i>Without testosterone indications</i>	508,705	508,705	707,005	19,542,766	65,358,255	53,008.9	86,697,574	197,027,457.6	586.76	38.42	1.39	27.64
Androgel												
<i>With testosterone indications</i>	125,560	125,560	184,593	6,176,249	29,141,687	16,909.6	17,491,834	12,629,732.8	717.82	49.19	1.47	33.46
<i>Without testosterone indications</i>	192,132	192,132	279,377	9,372,057	44,418,417	25,659.3	86,697,574	197,216,173.6	221.61	48.78	1.45	33.55
Axiron												
<i>With testosterone indications</i>	8,251	8,251	10,522	320,207	1,008,394	876.7	17,491,834	12,652,463.9	47.17	38.81	1.28	30.43
<i>Without testosterone indications</i>	11,227	11,227	14,174	432,456	1,358,190	1,184.0	86,697,574	197,328,615.5	12.95	38.52	1.26	30.51
Fortesta												
<i>With testosterone indications</i>	4,148	4,148	5,561	165,556	352,364	453.3	17,491,834	12,652,613.5	23.71	39.91	1.34	29.77
<i>Without testosterone indications</i>	5,660	5,660	7,486	224,315	475,665	614.1	86,697,574	197,328,991.0	6.53	39.63	1.32	29.96
Methyltestosterone												
<i>With testosterone indications</i>	1,287	1,287	2,090	82,545	95,820	226.0	17,491,834	12,652,433.5	7.36	64.14	1.62	39.50
<i>Without testosterone indications</i>	3,018	3,018	4,548	187,855	190,966	514.3	86,697,574	197,325,998.4	3.48	62.24	1.51	41.30
Striant												
<i>With testosterone indications</i>	415	415	520	17,999	34,230	49.3	17,491,834	12,652,756.8	2.37	43.37	1.25	34.61
<i>Without testosterone indications</i>	659	659	796	27,092	50,720	74.2	86,697,574	197,329,385.5	0.76	41.11	1.21	34.04
Intramuscular Testosterone Other												
<i>With testosterone indications</i>	4,631	4,631	5,517	220,040	32,435	602.4	17,491,834	12,651,943.3	26.48	47.51	1.19	39.88
<i>Without testosterone indications</i>	7,757	7,757	9,106	358,124	64,623	980.5	86,697,574	197,325,195.1	8.95	46.17	1.17	39.33
Testosterone Cypionate												
<i>With testosterone indications</i>	58,516	58,516	86,032	3,261,677	495,674	8,930.0	17,491,834	12,643,704.1	334.53	55.74	1.47	37.91
<i>Without testosterone indications</i>	87,336	87,336	125,719	4,787,584	747,819	13,107.7	86,697,574	197,292,158.6	100.74	54.82	1.44	38.08
Transdermal Testosterone												
<i>With testosterone indications</i>	18,507	18,507	25,867	898,226	950,331	2,459.2	17,491,834	12,648,730.3	105.80	48.53	1.40	34.72
<i>Without testosterone indications</i>	29,663	29,663	41,330	1,439,900	1,522,232	3,942.2	86,697,574	197,308,015.8	34.21	48.54	1.39	34.84
Testim												
<i>With testosterone indications</i>	46,781	46,781	72,096	2,360,454	12,681,591	6,462.6	17,491,834	12,645,084.7	267.44	50.46	1.54	32.74
<i>Without testosterone indications</i>	66,062	66,062	100,624	3,306,519	17,633,471	9,052.8	86,697,574	197,295,897.9	76.20	50.05	1.52	32.86
Testopel												
<i>With testosterone indications</i>	474	474	478	15,722	6,401	43.0	17,491,834	12,652,686.1	2.71	33.17	1.01	32.89
<i>Without testosterone indications</i>	537	537	544	18,423	7,195	50.4	86,697,574	197,329,570.1	0.62	34.31	1.01	33.87
Injection, testosterone cypionate, up to 100 mg (J1070)												
<i>With testosterone indications</i>	15,891	15,891	15,904	15,904	15,904	43.5	17,491,834	12,649,001.7	90.85	1.00	1.00	1.00
<i>Without testosterone indications</i>	31,117	31,117	31,138	31,138	31,138	85.3	86,697,574	197,304,302.6	35.89	1.00	1.00	1.00
Injection, testosterone cypionate, 1 cc, 200 mg (J1080)												
<i>With testosterone indications</i>	53,929	53,929	53,995	53,995	53,995	147.8	17,491,834	12,641,951.0	308.31	1.00	1.00	1.00
<i>Without testosterone indications</i>	91,818	91,818	91,922	91,922	91,922	251.7	86,697,574	197,273,978.1	105.91	1.00	1.00	1.00
Injection, testosterone enanthate, up to 100 mg (J3120)												
<i>With testosterone indications</i>	1,387	1,387	1,388	1,388	1,388	3.8	17,491,834	12,652,397.3	7.93	1.00	1.00	1.00
<i>Without testosterone indications</i>	2,797	2,797	2,799	2,799	2,799	7.7	86,697,574	197,327,545.5	3.23	1.00	1.00	1.00
Injection, testosterone enanthate, up to 200 mg (J3130)												
<i>With testosterone indications</i>	5,856	5,856	5,864	5,864	5,864	16.1	17,491,834	12,651,171.6	33.48	1.00	1.00	1.00
<i>Without testosterone indications</i>	10,377	10,377	10,389	10,389	10,389	28.4	86,697,574	197,321,526.1	11.97	1.00	1.00	1.00
Injection, testosterone suspension, up to 50 mg (J3140)												
<i>With testosterone indications</i>	793	793	795	795	795	2.2	17,491,834	12,652,567.6	4.53	1.00	1.00	1.00
<i>Without testosterone indications</i>	1,471	1,471	1,473	1,473	1,473	4.0	86,697,574	197,328,540.7	1.70	1.00	1.00	1.00
Injection, testosterone propionate, up to 100 mg (J3150)												
<i>With testosterone indications</i>	903	903	904	904	904	2.5	17,491,834	12,652,581.7	5.16	1.00	1.00	1.00
<i>Without testosterone indications</i>	1,817	1,817	1,820	1,820	1,820	5.0	86,697,574	197,328,296.4	2.10	1.00	1.00	1.00
Testosterone pellet, 75mg (S0189)												
<i>With testosterone indications</i>	5,305	5,305	5,307	5,307	5,307	14.5	17,491,834	12,651,829.6	30.33	1.00	1.00	1.00
<i>Without testosterone indications</i>	7,191	7,191	7,194	7,194	7,194	19.7	86,697,574	197,326,392.1	8.29	1.00	1.00	1.00

Table 2. Summary of Incident Testosterone use in the MSDD between January 1, 2007 and May 31, 2013, by Testosterone Product, Pre-existing Conditions, and Age Group

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
All Testosterone Products												
<i>With testosterone indications</i>												
0 to 39 Years	49,711	49,711	72,287	1,884,383	6,039,258	5,085.8	6,497,868	3,862,487.7	765.04	37.91	1.45	26.07
40 to 64 Years	236,070	236,070	338,344	9,585,630	33,303,960	25,999.2	8,434,579	6,093,732.6	2,798.84	40.61	1.43	28.33
65 to 74 Years	34,206	34,206	45,517	1,435,886	4,221,359	3,905.6	1,732,853	1,289,350.4	1,973.97	41.98	1.33	31.55
75+ Years	11,315	11,315	14,108	416,470	1,027,408	1,132.6	1,510,119	1,345,838.3	749.28	36.81	1.25	29.52
<i>Without testosterone indications</i>												
0 to 39 Years	75,963	75,963	106,287	2,688,440	8,228,136	7,262.6	50,927,770	101,444,421.2	149.16	35.39	1.40	25.29
40 to 64 Years	360,544	360,544	506,821	14,030,075	48,942,621	38,064.7	32,014,198	73,879,545.0	1,126.20	38.91	1.41	27.68
65 to 74 Years	54,130	54,130	71,586	2,197,546	6,602,165	5,976.9	5,575,788	12,488,710.3	970.80	40.60	1.32	30.70
75+ Years	18,068	18,068	22,311	626,705	1,585,333	1,704.6	3,229,930	9,214,781.1	559.39	34.69	1.23	28.09
AndroGel												
<i>With testosterone indications</i>												
0 to 39 Years	17,147	17,147	25,765	800,155	3,878,645	2,190.7	6,497,868	3,866,367.8	263.89	46.66	1.50	31.06
40 to 64 Years	91,743	91,743	136,152	4,528,478	21,452,774	12,398.3	8,436,872	6,118,803.0	1,087.41	49.36	1.48	33.26
65 to 74 Years	13,049	13,049	18,002	672,850	3,055,762	1,842.2	1,735,294	1,295,267.7	751.98	51.56	1.38	37.38
75+ Years	3,621	3,621	4,674	174,766	754,506	478.5	1,511,463	1,349,294.4	239.57	48.26	1.29	37.39
<i>Without testosterone indications</i>												
0 to 39 Years	24,451	24,451	36,039	1,124,010	5,460,606	3,077.4	50,927,770	101,468,454.2	48.01	45.97	1.47	31.19
40 to 64 Years	141,068	141,068	207,111	6,901,877	32,828,887	18,896.3	32,019,824	74,002,765.4	440.56	48.93	1.47	33.32
65 to 74 Years	20,993	20,993	28,917	1,071,424	4,934,390	2,933.4	5,581,933	12,515,250.5	376.09	51.04	1.38	37.05
75+ Years	5,620	5,620	7,310	274,746	1,194,533	752.2	3,232,964	9,229,703.4	173.83	48.89	1.30	37.58
Axiron												
<i>With testosterone indications</i>												
0 to 39 Years	1,056	1,056	1,306	39,371	123,841	107.8	6,497,868	3,868,580.6	16.25	37.28	1.24	30.15
40 to 64 Years	6,632	6,632	8,550	259,142	817,699	709.5	8,438,280	6,134,635.9	78.59	39.07	1.29	30.31
65 to 74 Years	489	489	585	18,954	58,620	51.9	1,736,748	1,298,510.7	28.16	38.76	1.20	32.40
75+ Years	74	74	81	2,740	8,235	7.5	1,512,079	1,350,736.7	4.89	37.03	1.09	33.83
<i>Without testosterone indications</i>												
0 to 39 Years	1,367	1,367	1,677	50,357	157,621	137.9	50,927,770	101,479,139.1	2.68	36.84	1.23	30.03
40 to 64 Years	9,032	9,032	11,515	350,314	1,102,872	959.1	32,023,154	74,082,560.3	28.20	38.79	1.27	30.42
65 to 74 Years	696	696	835	26,573	82,129	72.8	5,585,861	12,530,962.3	12.46	38.18	1.20	31.82
75+ Years	132	132	147	5,212	15,568	14.3	3,234,571	9,235,953.8	4.08	39.48	1.11	35.46
Fortesta												
<i>With testosterone indications</i>												
0 to 39 Years	610	610	792	22,982	48,505	62.9	6,497,868	3,868,598.1	9.39	37.68	1.30	29.02
40 to 64 Years	3,298	3,298	4,455	132,511	282,867	362.8	8,438,293	6,134,739.6	39.08	40.18	1.35	29.74
65 to 74 Years	212	212	273	8,710	18,296	23.8	1,736,763	1,298,532.8	12.21	41.08	1.29	31.90
75+ Years	28	28	41	1,353	2,696	3.7	1,512,079	1,350,743.0	1.85	48.32	1.46	33.00
<i>Without testosterone indications</i>												
0 to 39 Years	795	795	1,031	30,183	64,219	82.6	50,927,770	101,479,173.5	1.56	37.97	1.30	29.28
40 to 64 Years	4,522	4,522	6,014	179,570	381,805	491.6	32,023,194	74,082,831.4	14.12	39.71	1.33	29.86
65 to 74 Years	296	296	378	12,339	25,505	33.8	5,585,889	12,531,017.9	5.30	41.69	1.28	32.64
75+ Years	47	47	63	2,223	4,136	6.1	3,234,574	9,235,968.2	1.45	47.30	1.34	35.29
Methyltestosterone												
<i>With testosterone indications</i>												
0 to 39 Years	190	190	296	10,275	11,066	28.1	6,497,868	3,868,591.9	2.92	54.08	1.56	34.71
40 to 64 Years	963	963	1,582	63,285	74,412	173.3	8,438,289	6,134,622.3	11.41	65.72	1.64	40.00
65 to 74 Years	101	101	164	7,302	8,236	20.0	1,736,756	1,298,496.0	5.82	72.30	1.62	44.52
75+ Years	33	33	48	1,683	2,106	4.6	1,512,078	1,350,723.4	2.18	51.00	1.45	35.06
<i>Without testosterone indications</i>												
0 to 39 Years	435	435	622	22,185	22,121	60.7	50,927,770	101,478,873.2	0.85	51.00	1.43	35.67
40 to 64 Years	2,254	2,254	3,366	139,273	141,591	381.3	32,023,141	74,080,709.3	7.04	61.79	1.49	41.38
65 to 74 Years	261	261	445	20,891	22,222	57.2	5,585,831	12,530,588.0	4.67	80.04	1.70	46.95
75+ Years	68	68	115	5,506	5,032	15.1	3,234,547	9,235,827.8	2.10	80.97	1.69	47.88

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Striant												
<i>With testosterone indications</i>												
0 to 39 Years	81	81	94	3,036	5,949	8.3	6,497,868	3,868,618.7	1.25	37.48	1.16	32.30
40 to 64 Years	291	291	368	12,263	23,351	33.6	8,438,310	6,134,860.7	3.45	42.14	1.26	33.32
65 to 74 Years	33	33	36	1,410	2,650	3.9	1,736,770	1,298,533.7	1.90	42.73	1.09	39.17
75+ Years	10	10	22	1,290	2,280	3.5	1,512,083	1,350,743.7	0.66	129.00	2.20	58.64
<i>Without testosterone indications</i>												
0 to 39 Years	117	117	149	4,619	8,960	12.6	50,927,770	101,479,243.7	0.23	39.48	1.27	31.00
40 to 64 Years	468	468	552	18,323	34,285	50.2	32,023,223	74,083,164.3	1.46	39.15	1.18	33.19
65 to 74 Years	59	59	67	2,520	4,725	6.9	5,585,915	12,531,010.4	1.06	42.71	1.14	37.61
75+ Years	15	15	28	1,630	2,750	4.5	3,234,579	9,235,967.1	0.46	108.67	1.87	58.21
Intramuscular Testosterone Other												
<i>With testosterone indications</i>												
0 to 39 Years	967	967	1,150	39,894	6,285	109.2	6,497,868	3,868,478.1	14.88	41.26	1.19	34.69
40 to 64 Years	2,945	2,945	3,516	136,691	21,121	374.2	8,438,265	6,134,383.5	34.90	46.41	1.19	38.88
65 to 74 Years	518	518	609	31,272	3,580	85.6	1,736,723	1,298,426.1	29.83	60.37	1.18	51.35
75+ Years	201	201	242	12,183	1,448	33.4	1,512,044	1,350,655.6	13.29	60.61	1.20	50.34
<i>Without testosterone indications</i>												
0 to 39 Years	2,115	2,115	2,431	85,830	13,232	235.0	50,927,770	101,477,738.2	4.15	40.58	1.15	35.31
40 to 64 Years	4,557	4,557	5,410	208,668	43,873	571.3	32,023,105	74,081,211.2	14.23	45.79	1.19	38.57
65 to 74 Years	793	793	919	46,443	5,476	127.2	5,585,790	12,530,555.8	14.20	58.57	1.16	50.54
75+ Years	292	292	346	17,183	2,042	47.0	3,234,505	9,235,689.9	9.03	58.85	1.18	49.66
Testosterone Cypionate												
<i>With testosterone indications</i>												
0 to 39 Years	10,018	10,018	15,574	527,471	86,729	1,444.1	6,497,868	3,867,686.1	154.17	52.65	1.55	33.87
40 to 64 Years	39,154	39,154	57,753	2,109,972	330,914	5,776.8	8,437,748	6,129,091.9	464.03	53.89	1.48	36.53
65 to 74 Years	6,894	6,894	9,450	461,765	57,904	1,264.2	1,736,169	1,297,029.3	397.08	66.98	1.37	48.86
75+ Years	2,450	2,450	3,255	162,469	20,127	444.8	1,511,705	1,349,896.7	162.07	66.31	1.33	49.91
<i>Without testosterone indications</i>												
0 to 39 Years	15,754	15,754	23,343	809,119	136,693	2,215.2	50,927,770	101,473,925.6	30.93	51.36	1.48	34.66
40 to 64 Years	57,713	57,713	83,555	3,059,672	493,261	8,376.9	32,021,919	74,059,682.9	180.23	53.02	1.45	36.62
65 to 74 Years	10,295	10,295	14,084	683,207	87,940	1,870.5	5,584,574	12,525,569.5	184.35	66.36	1.37	48.51
75+ Years	3,574	3,574	4,737	235,586	29,926	645.0	3,233,808	9,232,980.6	110.52	65.92	1.33	49.73
Transdermal Testosterone												
<i>With testosterone indications</i>												
0 to 39 Years	2,560	2,560	3,511	113,185	120,060	309.9	6,497,868	3,868,253.1	39.40	44.21	1.37	32.24
40 to 64 Years	13,429	13,429	18,758	647,026	684,735	1,771.5	8,438,121	6,132,157.2	159.15	48.18	1.40	34.49
65 to 74 Years	1,844	1,844	2,668	101,620	107,575	278.2	1,736,495	1,297,877.3	106.19	55.11	1.45	38.09
75+ Years	674	674	930	36,395	37,961	99.6	1,511,955	1,350,442.7	44.58	54.00	1.38	39.13
<i>Without testosterone indications</i>												
0 to 39 Years	3,974	3,974	5,447	172,512	183,117	472.3	50,927,770	101,477,334.5	7.80	43.41	1.37	31.67
40 to 64 Years	21,451	21,451	29,855	1,033,503	1,093,029	2,829.6	32,022,658	74,068,616.6	66.99	48.18	1.39	34.62
65 to 74 Years	3,095	3,095	4,478	173,097	182,979	473.9	5,585,063	12,527,629.3	55.42	55.93	1.45	38.65
75+ Years	1,143	1,143	1,550	60,788	63,107	166.4	3,234,257	9,234,435.4	35.34	53.18	1.36	39.22
Testim												
<i>With testosterone indications</i>												
0 to 39 Years	6,642	6,642	10,158	313,459	1,690,439	858.2	6,497,868	3,867,923.4	102.22	47.19	1.53	30.86
40 to 64 Years	35,767	35,767	55,682	1,823,958	9,818,844	4,993.7	8,437,803	6,129,469.8	423.89	51.00	1.56	32.76
65 to 74 Years	3,527	3,527	5,121	181,357	958,642	496.5	1,736,241	1,297,416.7	203.14	51.42	1.45	35.41
75+ Years	845	845	1,135	41,680	213,666	114.1	1,511,873	1,350,274.8	55.89	49.33	1.34	36.72
<i>Without testosterone indications</i>												
0 to 39 Years	8,749	8,749	13,154	407,556	2,190,996	1,115.8	50,927,770	101,476,112.7	17.18	46.58	1.50	30.98
40 to 64 Years	50,661	50,661	77,995	2,562,970	13,692,466	7,017.0	32,022,115	74,059,359.0	158.21	50.59	1.54	32.86
65 to 74 Years	5,348	5,348	7,723	272,875	1,427,250	747.1	5,584,642	12,526,258.2	95.76	51.02	1.44	35.33
75+ Years	1,304	1,304	1,752	63,118	322,759	172.8	3,234,147	9,234,167.9	40.32	48.40	1.34	36.03
Testopel												
<i>With testosterone indications</i>												
0 to 39 Years	67	67	67	2,060	991	5.6	6,497,868	3,868,617.2	1.03	30.75	1.00	30.75
40 to 64 Years	352	352	356	11,061	4,799	30.3	8,438,295	6,134,795.1	4.17	31.42	1.01	31.07
65 to 74 Years	44	44	44	2,260	499	6.2	1,736,773	1,298,528.9	2.53	51.36	1.00	51.36
75+ Years	11	11	11	341	112	0.9	1,512,082	1,350,744.9	0.73	31.00	1.00	31.00

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Without testosterone indications												
0 to 39 Years	71	71	71	2,221	1,029	6.1	50,927,770	101,479,271.6	0.14	31.28	1.00	31.28
40 to 64 Years	398	398	404	12,613	5,339	34.5	32,023,216	74,083,281.0	1.24	31.69	1.02	31.22
65 to 74 Years	53	53	54	2,828	675	7.7	5,585,930	12,531,043.4	0.95	53.36	1.02	52.37
75+ Years	15	15	15	761	152	2.1	3,234,580	9,235,974.1	0.46	50.73	1.00	50.73
Injection, testosterone cypionate, up to 100 mg (J1070)												
With testosterone indications												
0 to 39 Years	2,914	2,914	2,918	2,918	2,918	8.0	6,497,868	3,868,151.4	44.85	1.00	1.00	1.00
40 to 64 Years	10,754	10,754	10,761	10,761	10,761	29.5	8,438,065	6,132,384.9	127.45	1.00	1.00	1.00
65 to 74 Years	1,577	1,577	1,579	1,579	1,579	4.3	1,736,606	1,298,050.5	90.81	1.00	1.00	1.00
75+ Years	646	646	646	646	646	1.8	1,511,967	1,350,414.9	42.73	1.00	1.00	1.00
Without testosterone indications												
0 to 39 Years	6,019	6,019	6,025	6,025	6,025	16.5	50,927,770	101,475,079.4	11.82	1.00	1.00	1.00
40 to 64 Years	20,913	20,913	20,925	20,925	20,925	57.3	32,022,440	74,066,644.1	65.31	1.00	1.00	1.00
65 to 74 Years	2,915	2,915	2,917	2,917	2,917	8.0	5,585,386	12,528,413.8	52.19	1.00	1.00	1.00
75+ Years	1,270	1,270	1,271	1,271	1,271	3.5	3,234,275	9,234,165.3	39.27	1.00	1.00	1.00
Injection, testosterone cypionate, 1 cc, 200 mg (J1080)												
With testosterone indications												
0 to 39 Years	8,372	8,372	8,385	8,385	8,385	23.0	6,497,868	3,867,528.9	128.84	1.00	1.00	1.00
40 to 64 Years	35,748	35,748	35,792	35,792	35,792	98.0	8,437,682	6,128,170.8	423.67	1.00	1.00	1.00
65 to 74 Years	6,857	6,857	6,864	6,864	6,864	18.8	1,736,094	1,296,791.1	394.97	1.00	1.00	1.00
75+ Years	2,952	2,952	2,954	2,954	2,954	8.1	1,511,624	1,349,460.2	195.29	1.00	1.00	1.00
Without testosterone indications												
0 to 39 Years	13,983	13,983	14,003	14,003	14,003	38.3	50,927,770	101,472,892.9	27.46	1.00	1.00	1.00
40 to 64 Years	61,008	61,008	61,078	61,078	61,078	167.2	32,021,653	74,048,587.7	190.52	1.00	1.00	1.00
65 to 74 Years	11,685	11,685	11,696	11,696	11,696	32.0	5,584,204	12,522,408.6	209.25	1.00	1.00	1.00
75+ Years	5,142	5,142	5,145	5,145	5,145	14.1	3,233,484	9,230,088.9	159.02	1.00	1.00	1.00
Injection, testosterone enanthate, up to 100 mg (J3120)												
With testosterone indications												
0 to 39 Years	222	222	222	222	222	0.6	6,497,868	3,868,582.9	3.42	1.00	1.00	1.00
40 to 64 Years	884	884	885	885	885	2.4	8,438,296	6,134,661.3	10.48	1.00	1.00	1.00
65 to 74 Years	188	188	188	188	188	0.5	1,736,758	1,298,459.2	10.82	1.00	1.00	1.00
75+ Years	93	93	93	93	93	0.3	1,512,067	1,350,693.8	6.15	1.00	1.00	1.00
Without testosterone indications												
0 to 39 Years	568	568	569	569	569	1.6	50,927,770	101,478,840.0	1.12	1.00	1.00	1.00
40 to 64 Years	1,700	1,700	1,701	1,701	1,701	4.7	32,023,182	74,082,261.0	5.31	1.00	1.00	1.00
65 to 74 Years	358	358	358	358	358	1.0	5,585,880	12,530,725.8	6.41	1.00	1.00	1.00
75+ Years	171	171	171	171	171	0.5	3,234,547	9,235,718.7	5.29	1.00	1.00	1.00
Injection, testosterone enanthate, up to 200 mg (J3130)												
With testosterone indications												
0 to 39 Years	815	815	815	815	815	2.2	6,497,868	3,868,493.7	12.54	1.00	1.00	1.00
40 to 64 Years	3,859	3,859	3,866	3,866	3,866	10.6	8,438,247	6,133,953.4	45.73	1.00	1.00	1.00
65 to 74 Years	791	791	791	791	791	2.2	1,736,653	1,298,200.3	45.55	1.00	1.00	1.00
75+ Years	391	391	392	392	392	1.1	1,512,012	1,350,524.1	25.86	1.00	1.00	1.00
Without testosterone indications												
0 to 39 Years	1,457	1,457	1,457	1,457	1,457	4.0	50,927,770	101,478,329.1	2.86	1.00	1.00	1.00
40 to 64 Years	6,778	6,778	6,788	6,788	6,788	18.6	32,023,062	74,078,568.4	21.17	1.00	1.00	1.00
65 to 74 Years	1,429	1,429	1,429	1,429	1,429	3.9	5,585,626	12,529,628.1	25.58	1.00	1.00	1.00
75+ Years	713	713	715	715	715	2.0	3,234,392	9,235,000.4	22.04	1.00	1.00	1.00
Injection, testosterone suspension, up to 50 mg (J3140)												
With testosterone indications												
0 to 39 Years	151	151	151	151	151	0.4	6,497,868	3,868,591.7	2.32	1.00	1.00	1.00
40 to 64 Years	534	534	535	535	535	1.5	8,438,300	6,134,743.3	6.33	1.00	1.00	1.00
65 to 74 Years	69	69	70	70	70	0.2	1,736,769	1,298,509.7	3.97	1.01	1.01	1.00
75+ Years	39	39	39	39	39	0.1	1,512,080	1,350,722.9	2.58	1.00	1.00	1.00
Without testosterone indications												
0 to 39 Years	286	286	286	286	286	0.8	50,927,770	101,479,055.2	0.56	1.00	1.00	1.00
40 to 64 Years	990	990	991	991	991	2.7	32,023,201	74,082,700.1	3.09	1.00	1.00	1.00
65 to 74 Years	122	122	123	123	123	0.3	5,585,907	12,530,929.2	2.18	1.01	1.01	1.00
75+ Years	73	73	73	73	73	0.2	3,234,568	9,235,856.3	2.26	1.00	1.00	1.00

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Injection, testosterone propionate, up to 100 mg (J3150)												
<i>With testosterone indications</i>												
0 to 39 Years	144	144	144	144	144	0.4	6,497,868	3,868,595.3	2.22	1.00	1.00	1.00
40 to 64 Years	633	633	634	634	634	1.7	8,438,295	6,134,741.6	7.50	1.00	1.00	1.00
65 to 74 Years	84	84	84	84	84	0.2	1,736,769	1,298,517.7	4.84	1.00	1.00	1.00
75+ Years	42	42	42	42	42	0.1	1,512,077	1,350,727.2	2.78	1.00	1.00	1.00
<i>Without testosterone indications</i>												
0 to 39 Years	241	241	242	242	242	0.7	50,927,770	101,479,128.1	0.47	1.00	1.00	1.00
40 to 64 Years	1,316	1,316	1,318	1,318	1,318	3.6	32,023,196	74,082,369.3	4.11	1.00	1.00	1.00
65 to 74 Years	178	178	178	178	178	0.5	5,585,896	12,530,928.5	3.19	1.00	1.00	1.00
75+ Years	82	82	82	82	82	0.2	3,234,560	9,235,870.5	2.54	1.00	1.00	1.00
Testosterone pellet, 75mg (S0189)												
<i>With testosterone indications</i>												
0 to 39 Years	600	600	601	601	601	1.6	6,497,868	3,868,550.2	9.23	1.00	1.00	1.00
40 to 64 Years	4,341	4,341	4,342	4,342	4,342	11.9	8,438,255	6,134,087.7	51.44	1.00	1.00	1.00
65 to 74 Years	320	320	320	320	320	0.9	1,736,727	1,298,457.9	18.43	1.00	1.00	1.00
75+ Years	44	44	44	44	44	0.1	1,512,075	1,350,733.8	2.91	1.00	1.00	1.00
<i>Without testosterone indications</i>												
0 to 39 Years	778	778	779	779	779	2.1	50,927,770	101,479,057.5	1.53	1.00	1.00	1.00
40 to 64 Years	5,976	5,976	5,978	5,978	5,978	16.4	32,023,137	74,080,545.7	18.66	1.00	1.00	1.00
65 to 74 Years	386	386	386	386	386	1.1	5,585,834	12,530,846.6	6.91	1.00	1.00	1.00
75+ Years	51	51	51	51	51	0.1	3,234,563	9,235,942.2	1.58	1.00	1.00	1.00

Table 3. Summary of Incident Testosterone use in the MSDD between January 1, 2007 and May 31, 2013, by Testosterone Product, Pre-existing Conditions, and Sex

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
All Testosterone Products												
<i>With testosterone indications</i>												
Female	13,804	13,804	14,625	221,859	417,487	605.0	10,851,997	8,247,670.7	127.20	16.07	1.06	15.17
Male	317,403	317,403	455,494	13,096,902	44,162,082	35,508.4	6,634,389	4,340,216.6	4,784.21	41.26	1.44	28.75
Unknown	95	95	137	3,608	12,415	9.8	5,448	3,521.7	1,743.76	37.98	1.44	26.34
<i>Without testosterone indications</i>												
Female	35,316	35,316	37,431	548,262	940,800	1,495.6	44,148,716	101,832,511.7	79.99	15.52	1.06	14.65
Male	473,246	473,246	669,383	18,989,607	64,400,668	51,499.9	42,529,182	95,159,913.9	1,112.76	40.13	1.41	28.37
Unknown	143	143	191	4,897	16,787	13.3	19,676	35,031.9	726.77	34.24	1.34	25.64
AndroGel												
<i>With testosterone indications</i>												
Female	1,578	1,578	1,738	59,524	220,961	163.0	10,851,997	8,251,919.9	14.54	37.72	1.10	34.25
Male	123,930	123,930	182,781	6,114,504	28,911,194	16,740.6	6,634,389	4,374,286.1	1,867.99	49.34	1.47	33.45
Unknown	52	52	74	2,221	9,533	6.1	5,448	3,526.8	954.48	42.71	1.42	30.01
<i>Without testosterone indications</i>												
Female	3,764	3,764	4,172	144,067	520,112	394.4	44,148,716	101,868,278.0	8.53	38.27	1.11	34.53
Male	188,293	188,293	275,101	9,224,860	43,885,163	25,256.3	42,529,182	95,312,839.1	442.74	48.99	1.46	33.53
Unknown	75	75	104	3,130	13,143	8.6	19,676	35,056.5	381.18	41.73	1.39	30.10
Axiron												
<i>With testosterone indications</i>												
Female	28	28	32	1,124	2,880	3.1	10,851,997	8,252,533.3	0.26	40.14	1.14	35.13
Male	8,219	8,219	10,486	318,963	1,005,154	873.3	6,634,389	4,396,398.9	123.88	38.81	1.28	30.42
Unknown	4	4	4	120	360	0.3	5,448	3,531.7	73.42	30.00	1.00	30.00
<i>Without testosterone indications</i>												
Female	46	46	50	1,746	4,753	4.8	44,148,716	101,873,075.0	0.10	37.96	1.09	34.92
Male	11,176	11,176	14,119	430,560	1,352,987	1,178.8	42,529,182	95,420,458.4	26.28	38.53	1.26	30.50
Unknown	5	5	5	150	450	0.4	19,676	35,082.1	25.41	30.00	1.00	30.00
Fortesta												
<i>With testosterone indications</i>												
Female	28	28	28	920	1,650	2.5	10,851,997	8,252,529.1	0.26	32.86	1.00	32.86
Male	4,118	4,118	5,530	164,546	350,534	450.5	6,634,389	4,396,553.1	62.07	39.96	1.34	29.76
Unknown	2	2	3	90	180	0.2	5,448	3,531.3	36.71	45.00	1.50	30.00
<i>Without testosterone indications</i>												
Female	53	53	54	1,675	3,220	4.6	44,148,716	101,873,062.3	0.12	31.60	1.02	31.02
Male	5,605	5,605	7,429	222,550	472,266	609.3	42,529,182	95,420,846.4	13.18	39.71	1.33	29.96
Unknown	2	2	3	90	180	0.2	19,676	35,082.3	10.16	45.00	1.50	30.00
Methyltestosterone												
<i>With testosterone indications</i>												
Female	506	506	671	33,636	16,534	92.1	10,851,997	8,252,346.4	4.66	66.47	1.33	50.13
Male	781	781	1,419	48,909	79,286	133.9	6,634,389	4,396,555.4	11.77	62.62	1.82	34.47
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	1,500	1,500	1,981	97,669	49,685	267.4	44,148,716	101,870,651.2	3.40	65.11	1.32	49.30
Male	1,518	1,518	2,567	90,186	141,281	246.9	42,529,182	95,420,264.4	3.57	59.41	1.69	35.13
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---
Striant												
<i>With testosterone indications</i>												
Female	10	10	10	347	339	1.0	10,851,997	8,252,531.7	0.09	34.70	1.00	34.70
Male	405	405	510	17,652	33,891	48.3	6,634,389	4,396,693.4	6.10	43.59	1.26	34.61
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	26	26	26	872	662	2.4	44,148,716	101,873,046.4	0.06	33.54	1.00	33.54
Male	633	633	770	26,220	50,058	71.8	42,529,182	95,421,256.3	1.49	41.42	1.22	34.05
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Intramuscular Testosterone Other												
<i>With testosterone indications</i>												
Female	137	137	143	5,110	1,494	14.0	10,851,997	8,252,488.8	1.26	37.30	1.04	35.73
Male	4,494	4,494	5,374	214,930	30,941	588.4	6,634,389	4,395,922.8	67.74	47.83	1.20	39.99
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	352	352	370	12,971	4,174	35.5	44,148,716	101,872,662.0	0.80	36.85	1.05	35.06
Male	7,405	7,405	8,736	345,153	60,448	945.0	42,529,182	95,417,450.3	17.41	46.61	1.18	39.51
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---
Testosterone Cypionate												
<i>With testosterone indications</i>												
Female	1,687	1,687	1,832	71,446	21,363	195.6	10,851,997	8,251,995.4	15.55	42.35	1.09	39.00
Male	56,818	56,818	84,188	3,189,831	474,265	8,733.3	6,634,389	4,388,177.0	856.42	56.14	1.48	37.89
Unknown	11	11	12	400	46	1.1	5,448	3,531.7	201.91	36.36	1.09	33.33
<i>Without testosterone indications</i>												
Female	4,564	4,564	5,060	193,292	53,747	529.2	44,148,716	101,868,508.7	10.34	42.35	1.11	38.20
Male	82,755	82,755	120,641	4,593,582	693,966	12,576.5	42,529,182	95,388,567.1	194.58	55.51	1.46	38.08
Unknown	17	17	18	710	106	1.9	19,676	35,082.8	86.40	41.76	1.06	39.44
Transdermal Testosterone												
<i>With testosterone indications</i>												
Female	201	201	224	7,110	7,867	19.5	10,851,997	8,252,467.9	1.85	35.37	1.11	31.74
Male	18,301	18,301	25,637	890,906	942,254	2,439.2	6,634,389	4,392,732.3	275.85	48.68	1.40	34.75
Unknown	5	5	6	210	210	0.6	5,448	3,530.1	91.78	42.00	1.20	35.00
<i>Without testosterone indications</i>												
Female	709	709	762	18,926	19,582	51.8	44,148,716	101,872,301.1	1.61	26.69	1.07	24.84
Male	28,948	28,948	40,561	1,420,734	1,502,380	3,889.8	42,529,182	95,400,641.8	68.07	49.08	1.40	35.03
Unknown	6	6	7	240	270	0.7	19,676	35,072.8	30.49	40.00	1.17	34.29
Testim												
<i>With testosterone indications</i>												
Female	1,074	1,074	1,130	35,459	134,633	97.1	10,851,997	8,252,154.0	9.90	33.02	1.05	31.38
Male	45,700	45,700	70,953	2,324,619	12,544,899	6,364.5	6,634,389	4,389,401.5	688.84	50.87	1.55	32.76
Unknown	7	7	13	376	2,060	1.0	5,448	3,529.2	128.49	53.71	1.86	28.92
<i>Without testosterone indications</i>												
Female	2,121	2,121	2,221	70,149	273,348	192.1	44,148,716	101,870,692.2	4.80	33.07	1.05	31.58
Male	63,930	63,930	98,386	3,235,851	17,357,048	8,859.3	42,529,182	95,390,128.5	150.32	50.62	1.54	32.89
Unknown	11	11	17	519	3,075	1.4	19,676	35,077.2	55.91	47.18	1.55	30.53
Testopel												
<i>With testosterone indications</i>												
Female	4	4	4	120	213	0.3	10,851,997	8,252,527.4	0.04	30.00	1.00	30.00
Male	470	470	474	15,602	6,188	42.7	6,634,389	4,396,627.0	7.08	33.20	1.01	32.92
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	5	5	5	121	214	0.3	44,148,716	101,873,070.9	0.01	24.20	1.00	24.20
Male	532	532	539	18,302	6,981	50.1	42,529,182	95,421,416.4	1.25	34.40	1.01	33.96
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---
Injection, testosterone cypionate, up to 100 mg (J1070)												
<i>With testosterone indications</i>												
Female	4,254	4,254	4,256	4,256	4,256	11.7	10,851,997	8,251,072.0	39.20	1.00	1.00	1.00
Male	11,635	11,635	11,646	11,646	11,646	31.9	6,634,389	4,394,398.0	175.37	1.00	1.00	1.00
Unknown	2	2	2	2	2	0.0	5,448	3,531.7	36.71	1.00	1.00	1.00
<i>Without testosterone indications</i>												
Female	11,427	11,427	11,431	11,431	11,431	31.3	44,148,716	101,859,955.2	25.88	1.00	1.00	1.00
Male	19,685	19,685	19,702	19,702	19,702	53.9	42,529,182	95,409,268.3	46.29	1.00	1.00	1.00
Unknown	5	5	5	5	5	0.0	19,676	35,079.2	25.41	1.00	1.00	1.00
Injection, testosterone cypionate, 1 cc, 200 mg (J1080)												
<i>With testosterone indications</i>												
Female	2,743	2,743	2,749	2,749	2,749	7.5	10,851,997	8,251,490.9	25.28	1.00	1.00	1.00
Male	51,176	51,176	51,236	51,236	51,236	140.3	6,634,389	4,386,928.3	771.37	1.00	1.00	1.00
Unknown	10	10	10	10	10	0.0	5,448	3,531.7	183.55	1.00	1.00	1.00

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Without testosterone indications												
Female	7,590	7,590	7,596	7,596	7,596	20.8	44,148,716	101,864,402.1	17.19	1.00	1.00	1.00
Male	84,206	84,206	84,304	84,304	84,304	230.8	42,529,182	95,374,497.6	198.00	1.00	1.00	1.00
Unknown	22	22	22	22	22	0.1	19,676	35,078.4	111.81	1.00	1.00	1.00
Injection, testosterone enanthate, up to 100 mg (J3120)												
With testosterone indications												
Female	219	219	219	219	219	0.6	10,851,997	8,252,456.6	2.02	1.00	1.00	1.00
Male	1,167	1,167	1,168	1,168	1,168	3.2	6,634,389	4,396,409.5	17.59	1.00	1.00	1.00
Unknown	1	1	1	1	1	0.0	5,448	3,531.3	18.36	1.00	1.00	1.00
Without testosterone indications												
Female	587	587	587	587	587	1.6	44,148,716	101,872,475.9	1.33	1.00	1.00	1.00
Male	2,209	2,209	2,211	2,211	2,211	6.1	42,529,182	95,419,987.2	5.19	1.00	1.00	1.00
Unknown	1	1	1	1	1	0.0	19,676	35,082.4	5.08	1.00	1.00	1.00
Injection, testosterone enanthate, up to 200 mg (J3130)												
With testosterone indications												
Female	226	226	226	226	226	0.6	10,851,997	8,252,437.0	2.08	1.00	1.00	1.00
Male	5,628	5,628	5,636	5,636	5,636	15.4	6,634,389	4,395,202.9	84.83	1.00	1.00	1.00
Unknown	2	2	2	2	2	0.0	5,448	3,531.7	36.71	1.00	1.00	1.00
Without testosterone indications												
Female	641	641	641	641	641	1.8	44,148,716	101,872,309.0	1.45	1.00	1.00	1.00
Male	9,732	9,732	9,744	9,744	9,744	26.7	42,529,182	95,414,135.4	22.88	1.00	1.00	1.00
Unknown	4	4	4	4	4	0.0	19,676	35,081.7	20.33	1.00	1.00	1.00
Injection, testosterone suspension, up to 50 mg (J3140)												
With testosterone indications												
Female	134	134	134	134	134	0.4	10,851,997	8,252,469.9	1.23	1.00	1.00	1.00
Male	659	659	661	661	661	1.8	6,634,389	4,396,566.0	9.93	1.00	1.00	1.00
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
Without testosterone indications												
Female	332	332	332	332	332	0.9	44,148,716	101,872,636.3	0.75	1.00	1.00	1.00
Male	1,139	1,139	1,141	1,141	1,141	3.1	42,529,182	95,420,821.6	2.68	1.00	1.00	1.00
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---
Injection, testosterone propionate, up to 100 mg (J3150)												
With testosterone indications												
Female	245	245	245	245	245	0.7	10,851,997	8,252,450.2	2.26	1.00	1.00	1.00
Male	658	658	659	659	659	1.8	6,634,389	4,396,599.9	9.92	1.00	1.00	1.00
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
Without testosterone indications												
Female	698	698	699	699	699	1.9	44,148,716	101,872,392.6	1.58	1.00	1.00	1.00
Male	1,119	1,119	1,121	1,121	1,121	3.1	42,529,182	95,420,821.0	2.63	1.00	1.00	1.00
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---
Testosterone pellet, 75mg (S0189)												
With testosterone indications												
Female	1,112	1,112	1,112	1,112	1,112	3.0	10,851,997	8,252,248.5	10.25	1.00	1.00	1.00
Male	4,192	4,192	4,194	4,194	4,194	11.5	6,634,389	4,396,049.6	63.19	1.00	1.00	1.00
Unknown	1	1	1	1	1	0.0	5,448	3,531.5	18.36	1.00	1.00	1.00
Without testosterone indications												
Female	2,383	2,383	2,384	2,384	2,384	6.5	44,148,716	101,871,177.8	5.40	1.00	1.00	1.00
Male	4,807	4,807	4,809	4,809	4,809	13.2	42,529,182	95,420,131.8	11.30	1.00	1.00	1.00
Unknown	1	1	1	1	1	0.0	19,676	35,082.6	5.08	1.00	1.00	1.00

Table 4. Summary of Incident Testosterone use in the MSDD between January 1, 2007 and May 31, 2013, by Testosterone Product, Pre-existing Conditions, and Year

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
All Testosterone Products												
<i>With testosterone indications</i>												
2007	12,727	12,727	19,695	598,429	2,232,281	1,616.1	2,535,964	922,538.6	501.86	47.02	1.55	30.38
2008	30,828	30,828	44,736	1,330,190	5,393,853	3,606.0	4,943,494	1,710,609.8	623.61	43.15	1.45	29.73
2009	51,143	51,143	73,798	2,174,214	8,545,032	5,895.6	5,887,371	2,316,053.2	868.69	42.51	1.44	29.46
2010	56,604	56,604	80,165	2,309,351	8,585,580	6,258.9	5,794,374	2,280,050.1	976.88	40.80	1.42	28.81
2011	63,748	63,748	90,810	2,563,730	8,158,735	6,942.3	5,745,106	2,290,541.3	1,109.61	40.22	1.42	28.23
2012	83,122	83,122	117,939	3,254,945	8,939,963	8,838.9	5,662,001	2,264,292.1	1,468.07	39.16	1.42	27.60
2013	33,130	33,130	43,113	1,091,510	2,736,540	2,965.5	3,358,494	807,323.9	986.45	32.95	1.30	25.32
<i>Without testosterone indications</i>												
2007	25,168	25,168	36,567	1,092,270	3,806,214	2,955.4	23,500,888	17,213,753.9	107.09	43.40	1.45	29.87
2008	55,043	55,043	76,786	2,197,256	8,636,203	5,962.5	44,724,089	28,393,783.3	123.07	39.92	1.40	28.62
2009	85,621	85,621	119,898	3,427,425	13,318,753	9,298.1	46,568,653	36,431,617.5	183.86	40.03	1.40	28.59
2010	87,999	87,999	122,908	3,450,021	12,788,880	9,354.1	44,748,221	35,163,461.1	196.65	39.21	1.40	28.07
2011	93,741	93,741	130,927	3,587,694	11,390,970	9,719.6	43,545,916	34,567,337.4	215.27	38.27	1.40	27.40
2012	115,984	115,984	161,734	4,350,535	11,849,908	11,811.3	42,408,793	33,339,111.6	273.49	37.51	1.39	26.90
2013	45,149	45,149	58,185	1,437,565	3,567,326	3,907.8	32,835,754	11,918,392.6	137.50	31.84	1.29	24.71
AndroGel												
<i>With testosterone indications</i>												
2007	4,580	4,580	8,012	283,233	1,517,128	775.4	2,535,964	922,627.3	180.60	61.84	1.75	35.35
2008	13,108	13,108	20,361	692,236	3,736,878	1,895.2	4,946,277	1,711,561.8	265.01	52.81	1.55	34.00
2009	23,503	23,503	35,489	1,203,521	6,435,999	3,295.1	5,895,862	2,319,014.2	398.64	51.21	1.51	33.91
2010	25,385	25,385	37,030	1,246,466	6,554,031	3,412.6	5,811,336	2,286,110.5	436.82	49.10	1.46	33.66
2011	23,202	23,202	33,350	1,120,110	5,188,644	3,066.7	5,769,793	2,299,722.2	402.13	48.28	1.44	33.59
2012	26,004	26,004	37,583	1,235,544	4,411,611	3,382.7	5,695,816	2,277,100.9	456.55	47.51	1.45	32.88
2013	9,778	9,778	12,768	395,139	1,297,396	1,081.8	3,388,747	813,595.8	288.54	40.41	1.31	30.95
<i>Without testosterone indications</i>												
2007	8,173	8,173	13,775	500,220	2,625,140	1,369.5	23,500,888	17,214,318.2	34.78	61.20	1.69	36.31
2008	22,224	22,224	33,777	1,153,610	6,158,898	3,158.4	44,733,494	28,399,643.0	49.68	51.91	1.52	34.15
2009	38,171	38,171	56,461	1,919,439	10,195,720	5,255.1	46,594,939	36,448,470.9	81.92	50.29	1.48	34.00
2010	39,209	39,209	56,746	1,906,235	9,939,896	5,219.0	44,796,711	35,195,727.7	87.53	48.62	1.45	33.59
2011	34,144	34,144	48,393	1,620,432	7,502,095	4,436.5	43,612,552	34,613,065.8	78.29	47.46	1.42	33.48
2012	36,620	36,620	52,430	1,722,230	6,186,702	4,715.2	42,495,000	33,398,872.0	86.17	47.03	1.43	32.85
2013	13,591	13,591	17,795	549,891	1,809,964	1,505.5	32,923,287	11,946,076.1	41.28	40.46	1.31	30.90
Axiron												
<i>With testosterone indications</i>												
2007	0	0	0	0	0	0.0	2,535,964	922,659.9	0.00	---	---	---
2008	0	0	0	0	0	0.0	4,947,436	1,711,962.2	0.00	---	---	---
2009	0	0	0	0	0	0.0	5,900,259	2,320,548.1	0.00	---	---	---
2010	0	0	0	0	0	0.0	5,821,710	2,289,825.0	0.00	---	---	---
2011	1,962	1,962	2,549	76,953	244,175	210.7	5,785,738	2,305,640.0	33.91	39.22	1.30	30.19
2012	4,349	4,349	5,648	173,201	546,581	474.2	5,716,060	2,284,932.6	76.08	39.83	1.30	30.67
2013	1,940	1,940	2,325	70,053	217,639	191.8	3,403,497	816,896.2	57.00	36.11	1.20	30.13
<i>Without testosterone indications</i>												
2007	0	0	0	0	0	0.0	23,500,888	17,214,512.1	0.00	---	---	---
2008	0	0	0	0	0	0.0	44,737,543	28,402,067.3	0.00	---	---	---
2009	0	0	0	0	0	0.0	46,609,109	36,456,923.4	0.00	---	---	---
2010	0	0	0	0	0	0.0	44,827,241	35,214,936.8	0.00	---	---	---
2011	2,609	2,609	3,390	103,173	327,121	282.5	43,657,540	34,642,668.9	5.98	39.55	1.30	30.43
2012	6,010	6,010	7,661	234,691	737,745	642.5	42,548,806	33,435,846.0	14.12	39.05	1.27	30.63
2013	2,608	2,608	3,123	94,592	293,324	259.0	32,970,708	11,961,661.0	7.91	36.27	1.20	30.29

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Fortesta												
<i>With testosterone indications</i>												
2007	0	0	0	0	0	0.0	2,535,964	922,659.9	0.00	---	---	---
2008	0	0	0	0	0	0.0	4,947,436	1,711,962.2	0.00	---	---	---
2009	0	0	0	0	0	0.0	5,900,259	2,320,548.1	0.00	---	---	---
2010	0	0	0	0	0	0.0	5,821,710	2,289,825.0	0.00	---	---	---
2011	1,205	1,205	1,596	46,951	99,425	128.5	5,785,738	2,305,635.6	20.83	38.96	1.32	29.42
2012	2,117	2,117	2,896	86,498	185,407	236.8	5,716,220	2,284,990.7	37.03	40.86	1.37	29.87
2013	826	826	1,069	32,107	67,532	87.9	3,403,972	816,992.0	24.27	38.87	1.29	30.03
<i>Without testosterone indications</i>												
2007	0	0	0	0	0	0.0	23,500,888	17,214,512.1	0.00	---	---	---
2008	0	0	0	0	0	0.0	44,737,543	28,402,067.3	0.00	---	---	---
2009	0	0	0	0	0	0.0	46,609,109	36,456,923.4	0.00	---	---	---
2010	0	0	0	0	0	0.0	44,827,241	35,214,936.8	0.00	---	---	---
2011	1,741	1,741	2,280	67,011	144,464	183.5	43,657,540	34,642,654.7	3.99	38.49	1.31	29.39
2012	2,815	2,815	3,799	114,861	242,408	314.5	42,549,055	33,435,938.7	6.62	40.80	1.35	30.23
2013	1,104	1,104	1,407	42,443	88,793	116.2	32,971,785	11,961,958.0	3.35	38.44	1.27	30.17
Methyltestosterone												
<i>With testosterone indications</i>												
2007	132	132	201	9,371	9,685	25.7	2,535,964	922,659.1	5.21	70.99	1.52	46.62
2008	223	223	328	12,897	14,836	35.3	4,947,397	1,711,947.4	4.51	57.83	1.47	39.32
2009	321	321	561	21,226	26,885	58.1	5,900,145	2,320,500.5	5.44	66.12	1.75	37.84
2010	248	248	406	16,523	18,788	45.2	5,821,517	2,289,744.4	4.26	66.63	1.64	40.70
2011	175	175	288	11,909	12,473	32.6	5,785,479	2,305,535.7	3.02	68.05	1.65	41.35
2012	150	150	243	8,465	10,520	23.2	5,716,279	2,284,989.4	2.62	56.43	1.62	34.84
2013	38	38	63	2,154	2,633	5.9	3,404,332	817,057.0	1.12	56.68	1.66	34.19
<i>Without testosterone indications</i>												
2007	418	418	638	31,395	32,210	86.0	23,500,888	17,214,494.8	1.78	75.11	1.53	49.21
2008	579	579	840	36,118	35,741	98.9	44,737,262	28,401,875.8	1.29	62.38	1.45	43.00
2009	757	757	1,164	45,196	47,872	123.7	46,608,465	36,456,469.8	1.62	59.70	1.54	38.83
2010	522	522	803	32,083	31,914	87.8	44,826,207	35,214,179.9	1.16	61.46	1.54	39.95
2011	364	364	536	22,211	21,198	60.8	43,656,276	34,641,686.4	0.83	61.02	1.47	41.44
2012	288	288	442	16,615	17,806	45.5	42,548,510	33,435,314.5	0.68	57.69	1.53	37.59
2013	90	90	125	4,237	4,224	11.6	32,972,054	11,961,977.1	0.27	47.08	1.39	33.90
Striant												
<i>With testosterone indications</i>												
2007	24	24	48	2,249	4,136	6.2	2,535,964	922,659.7	0.95	93.71	2.00	46.85
2008	60	60	69	2,407	4,705	6.6	4,947,433	1,711,960.4	1.21	40.12	1.15	34.88
2009	63	63	74	2,572	4,973	7.0	5,900,242	2,320,543.5	1.07	40.83	1.17	34.76
2010	62	62	69	2,360	4,206	6.5	5,821,658	2,289,806.5	1.06	38.06	1.11	34.20
2011	88	88	128	4,017	7,544	11.0	5,785,681	2,305,623.1	1.52	45.65	1.45	31.38
2012	92	92	105	3,599	7,136	9.9	5,716,474	2,285,076.6	1.61	39.12	1.14	34.28
2013	26	26	27	795	1,530	2.2	3,404,456	817,087.1	0.76	30.58	1.04	29.44
<i>Without testosterone indications</i>												
2007	52	52	78	3,325	6,102	9.1	23,500,888	17,214,510.4	0.22	63.94	1.50	42.63
2008	106	106	117	4,017	7,555	11.0	44,737,512	28,402,048.3	0.24	37.90	1.10	34.33
2009	103	103	117	3,924	7,583	10.7	46,609,021	36,456,870.9	0.22	38.10	1.14	33.54
2010	100	100	119	3,947	6,920	10.8	44,827,108	35,214,848.0	0.22	39.47	1.19	33.17
2011	131	131	175	5,447	10,284	14.9	43,657,371	34,642,551.1	0.30	41.58	1.34	31.13
2012	130	130	152	5,327	10,213	14.6	42,549,658	33,436,248.5	0.31	40.98	1.17	35.05
2013	37	37	38	1,105	2,063	3.0	32,973,041	11,962,308.5	0.11	29.86	1.03	29.08

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Intramuscular Testosterone Other												
<i>With testosterone indications</i>												
2007	291	291	344	14,137	2,564	38.7	2,535,964	922,656.6	11.47	48.58	1.18	41.10
2008	480	480	556	21,727	4,407	59.5	4,947,331	1,711,925.6	9.70	45.26	1.16	39.08
2009	874	874	1,048	39,955	6,086	109.4	5,900,045	2,320,467.2	14.81	45.72	1.20	38.13
2010	869	869	1,041	39,739	5,623	108.8	5,821,258	2,289,671.3	14.93	45.73	1.20	38.17
2011	783	783	936	39,877	5,165	109.2	5,785,099	2,305,413.5	13.53	50.93	1.20	42.60
2012	977	977	1,185	49,171	6,488	134.6	5,715,779	2,284,825.8	17.09	50.33	1.21	41.49
2013	357	357	407	15,434	2,102	42.3	3,403,961	816,983.3	10.49	43.23	1.14	37.92
<i>Without testosterone indications</i>												
2007	699	699	781	32,885	5,465	90.0	23,500,888	17,214,496.1	2.97	47.05	1.12	42.11
2008	966	966	1,148	44,226	8,199	121.1	44,737,158	28,401,855.4	2.16	45.78	1.19	38.52
2009	1,450	1,450	1,710	64,288	21,390	176.0	46,608,315	36,456,457.0	3.11	44.34	1.18	37.60
2010	1,424	1,424	1,675	64,324	9,190	176.1	44,825,860	35,214,094.2	3.18	45.17	1.18	38.40
2011	1,284	1,284	1,526	62,515	8,288	171.2	43,655,715	34,641,534.0	2.94	48.69	1.19	40.97
2012	1,443	1,443	1,717	69,444	9,238	190.1	42,547,697	33,434,979.3	3.39	48.12	1.19	40.44
2013	491	491	549	20,442	2,853	56.0	32,971,376	11,961,779.3	1.49	41.63	1.12	37.23
Testosterone Cypionate												
<i>With testosterone indications</i>												
2007	1,781	1,781	2,493	104,710	18,369	286.7	2,535,964	922,639.0	70.23	58.79	1.40	42.00
2008	3,787	3,787	5,081	204,845	37,191	560.8	4,946,810	1,711,751.7	76.55	54.09	1.34	40.32
2009	7,134	7,134	9,905	396,350	69,472	1,085.1	5,898,548	2,319,966.0	120.95	55.56	1.39	40.02
2010	9,024	9,024	13,285	523,441	84,071	1,433.1	5,817,909	2,288,539.1	155.11	58.01	1.47	39.40
2011	11,876	11,876	18,515	702,740	101,708	1,924.0	5,779,592	2,303,475.2	205.48	59.17	1.56	37.96
2012	17,107	17,107	26,153	977,894	132,661	2,677.3	5,707,713	2,281,871.5	299.72	57.16	1.53	37.39
2013	7,807	7,807	10,600	351,697	52,201	962.9	3,396,617	815,461.5	229.85	45.05	1.36	33.18
<i>Without testosterone indications</i>												
2007	3,684	3,684	4,824	206,516	39,257	565.4	23,500,888	17,214,413.9	15.68	56.06	1.31	42.81
2008	6,712	6,712	8,729	352,247	67,703	964.4	44,735,525	28,400,997.0	15.00	52.48	1.30	40.35
2009	11,511	11,511	15,515	626,321	112,505	1,714.8	46,603,967	36,454,066.4	24.70	54.41	1.35	40.37
2010	13,596	13,596	19,708	772,685	126,284	2,115.5	44,817,175	35,209,193.4	30.34	56.83	1.45	39.21
2011	17,257	17,257	26,524	1,002,580	146,357	2,744.9	43,642,312	34,633,656.1	39.54	58.10	1.54	37.80
2012	23,870	23,870	36,039	1,346,876	184,634	3,687.5	42,529,120	33,423,697.9	56.13	56.43	1.51	37.37
2013	10,706	10,706	14,380	480,359	71,078	1,315.2	32,952,273	11,956,133.9	32.49	44.87	1.34	33.40
Transdermal Testosterone												
<i>With testosterone indications</i>												
2007	1,134	1,134	1,750	68,777	73,681	188.3	2,535,964	922,651.2	44.72	60.65	1.54	39.30
2008	2,215	2,215	3,125	111,402	118,212	305.0	4,947,123	1,711,850.2	44.77	50.29	1.41	35.65
2009	3,370	3,370	4,651	161,394	170,690	441.9	5,899,254	2,320,182.7	57.13	47.89	1.38	34.70
2010	3,643	3,643	5,119	177,355	188,367	485.6	5,819,761	2,289,087.7	62.60	48.68	1.41	34.65
2011	3,118	3,118	4,350	152,275	161,036	416.9	5,782,954	2,304,587.2	53.92	48.84	1.40	35.01
2012	3,328	3,328	4,631	155,676	164,651	426.2	5,713,237	2,283,813.1	58.25	46.78	1.39	33.62
2013	1,699	1,699	2,241	71,347	73,693	195.3	3,402,091	816,558.3	49.94	41.99	1.32	31.84
<i>Without testosterone indications</i>												
2007	2,025	2,025	3,099	127,780	134,721	349.8	23,500,888	17,214,460.5	8.62	63.10	1.53	41.23
2008	3,908	3,908	5,470	194,927	207,444	533.7	44,736,439	28,401,399.3	8.74	49.88	1.40	35.64
2009	5,761	5,761	8,058	277,093	292,612	758.6	46,605,920	36,454,930.6	12.36	48.10	1.40	34.39
2010	5,901	5,901	8,289	285,189	301,549	780.8	44,821,302	35,210,969.8	13.17	48.33	1.40	34.41
2011	4,827	4,827	6,641	232,008	246,237	635.2	43,649,401	34,637,040.0	11.06	48.06	1.38	34.94
2012	4,871	4,871	6,686	224,415	237,493	614.4	42,540,298	33,429,624.2	11.45	46.07	1.37	33.56
2013	2,370	2,370	3,087	98,488	102,176	269.6	32,964,760	11,959,591.5	7.19	41.56	1.30	31.90

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Testim												
<i>With testosterone indications</i>												
2007	1,589	1,589	2,911	97,763	535,880	267.7	2,535,964	922,650.7	62.66	61.52	1.83	33.58
2008	4,837	4,837	7,410	250,092	1,333,350	684.7	4,947,027	1,711,818.2	97.78	51.70	1.53	33.75
2009	6,075	6,075	9,499	310,907	1,680,815	851.2	5,898,544	2,319,949.2	102.99	51.18	1.56	32.73
2010	6,488	6,488	9,824	319,623	1,715,019	875.1	5,818,299	2,288,578.6	111.51	49.26	1.51	32.53
2011	9,153	9,153	13,923	459,065	2,439,045	1,256.9	5,780,935	2,303,789.0	158.33	50.15	1.52	32.97
2012	13,684	13,684	21,472	705,031	3,812,786	1,930.3	5,709,926	2,282,514.9	239.65	51.52	1.57	32.83
2013	4,955	4,955	7,057	217,973	1,164,697	596.8	3,398,477	815,784.2	145.80	43.99	1.42	30.89
<i>Without testosterone indications</i>												
2007	2,625	2,625	4,589	159,915	855,811	437.8	23,500,888	17,214,457.5	11.17	60.92	1.75	34.85
2008	7,460	7,460	11,097	371,580	1,971,804	1,017.3	44,736,274	28,401,280.9	16.68	49.81	1.49	33.48
2009	9,134	9,134	14,144	465,283	2,494,171	1,273.9	46,604,362	36,454,061.8	19.60	50.94	1.55	32.90
2010	9,487	9,487	14,283	465,719	2,467,838	1,275.1	44,818,401	35,209,185.8	21.17	49.09	1.51	32.61
2011	12,656	12,656	19,142	631,904	3,340,066	1,730.1	43,645,237	34,634,382.0	29.00	49.93	1.51	33.01
2012	18,300	18,300	28,361	933,283	5,021,104	2,555.2	42,533,779	33,425,519.2	43.02	51.00	1.55	32.91
2013	6,400	6,400	9,008	278,835	1,482,677	763.4	32,956,351	11,957,010.7	19.42	43.57	1.41	30.95
Testopel												
<i>With testosterone indications</i>												
2007	18	18	19	565	249	1.5	2,535,964	922,659.9	0.71	31.39	1.06	29.74
2008	29	29	29	876	355	2.4	4,947,433	1,711,961.2	0.59	30.21	1.00	30.21
2009	69	69	69	2,127	956	5.8	5,900,241	2,320,541.8	1.17	30.83	1.00	30.83
2010	105	105	107	3,401	1,453	9.3	5,821,655	2,289,798.4	1.80	32.39	1.02	31.79
2011	133	133	134	5,006	1,867	13.7	5,785,651	2,305,600.9	2.30	37.64	1.01	37.36
2012	93	93	93	3,007	1,205	8.2	5,716,401	2,285,046.5	1.63	32.33	1.00	32.33
2013	27	27	27	740	316	2.0	3,404,399	817,077.4	0.79	27.41	1.00	27.41
<i>Without testosterone indications</i>												
2007	23	23	24	715	311	2.0	23,500,888	17,214,512.1	0.10	31.09	1.04	29.79
2008	36	36	38	1,326	456	3.6	44,737,536	28,402,064.3	0.08	36.83	1.06	34.89
2009	77	77	77	2,408	1,051	6.6	46,609,077	36,456,908.4	0.17	31.27	1.00	31.27
2010	121	121	123	3,831	1,623	10.5	44,827,166	35,214,887.3	0.27	31.66	1.02	31.15
2011	149	149	151	6,074	2,108	16.6	43,657,418	34,642,590.3	0.34	40.77	1.01	40.23
2012	100	100	100	3,213	1,282	8.8	42,549,659	33,436,283.4	0.24	32.13	1.00	32.13
2013	31	31	31	856	364	2.3	32,973,070	11,962,324.2	0.09	27.61	1.00	27.61
Injection, testosterone cypionate, up to 100 mg (J1070)												
<i>With testosterone indications</i>												
2007	673	673	674	674	674	1.8	2,535,964	922,649.9	26.54	1.00	1.00	1.00
2008	1,397	1,397	1,397	1,397	1,397	3.8	4,947,158	1,711,862.6	28.24	1.00	1.00	1.00
2009	2,433	2,433	2,437	2,437	2,437	6.7	5,899,414	2,320,245.2	41.24	1.00	1.00	1.00
2010	2,790	2,790	2,792	2,792	2,792	7.6	5,820,004	2,289,194.1	47.94	1.00	1.00	1.00
2011	3,156	3,156	3,161	3,161	3,161	8.7	5,783,378	2,304,738.3	54.57	1.00	1.00	1.00
2012	3,949	3,949	3,950	3,950	3,950	10.8	5,713,315	2,283,814.4	69.12	1.00	1.00	1.00
2013	1,493	1,493	1,493	1,493	1,493	4.1	3,401,678	816,497.2	43.89	1.00	1.00	1.00
<i>Without testosterone indications</i>												
2007	1,887	1,887	1,889	1,889	1,889	5.2	23,500,888	17,214,409.3	8.03	1.00	1.00	1.00
2008	3,542	3,542	3,542	3,542	3,542	9.7	44,736,333	28,401,192.1	7.92	1.00	1.00	1.00
2009	5,571	5,571	5,575	5,575	5,575	15.3	46,605,786	36,454,498.4	11.95	1.00	1.00	1.00
2010	5,553	5,553	5,555	5,555	5,555	15.2	44,821,002	35,210,342.1	12.39	1.00	1.00	1.00
2011	5,774	5,774	5,782	5,782	5,782	15.8	43,649,114	34,636,387.8	13.23	1.00	1.00	1.00
2012	6,459	6,459	6,463	6,463	6,463	17.7	42,539,305	33,428,526.0	15.18	1.00	1.00	1.00
2013	2,331	2,331	2,332	2,332	2,332	6.4	32,963,049	11,958,946.9	7.07	1.00	1.00	1.00

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Injection, testosterone cypionate, 1 cc, 200 mg (J1080)												
<i>With testosterone indications</i>												
2007	1,975	1,975	1,977	1,977	1,977	5.4	2,535,964	922,633.3	77.88	1.00	1.00	1.00
2008	4,122	4,122	4,132	4,132	4,132	11.3	4,946,637	1,711,705.6	83.33	1.00	1.00	1.00
2009	7,042	7,042	7,057	7,057	7,057	19.3	5,897,922	2,319,770.7	119.40	1.00	1.00	1.00
2010	8,921	8,921	8,934	8,934	8,934	24.5	5,816,961	2,288,201.7	153.36	1.00	1.00	1.00
2011	10,903	10,903	10,913	10,913	10,913	29.9	5,778,498	2,303,008.2	188.68	1.00	1.00	1.00
2012	14,883	14,883	14,896	14,896	14,896	40.8	5,706,408	2,281,336.4	260.81	1.00	1.00	1.00
2013	6,083	6,083	6,086	6,086	6,086	16.7	3,395,277	815,295.0	179.16	1.00	1.00	1.00
<i>Without testosterone indications</i>												
2007	4,208	4,208	4,215	4,215	4,215	11.5	23,500,888	17,214,350.6	17.91	1.00	1.00	1.00
2008	8,405	8,405	8,419	8,419	8,419	23.0	44,735,219	28,400,532.9	18.79	1.00	1.00	1.00
2009	13,161	13,161	13,189	13,189	13,189	36.1	46,602,300	36,452,300.8	28.24	1.00	1.00	1.00
2010	15,288	15,288	15,301	15,301	15,301	41.9	44,814,034	35,205,888.9	34.11	1.00	1.00	1.00
2011	18,076	18,076	18,093	18,093	18,093	49.5	43,638,305	34,629,163.8	41.42	1.00	1.00	1.00
2012	23,331	23,331	23,349	23,349	23,349	63.9	42,523,825	33,417,897.2	54.87	1.00	1.00	1.00
2013	9,349	9,349	9,356	9,356	9,356	25.6	32,946,137	11,953,843.9	28.38	1.00	1.00	1.00
Injection, testosterone enanthate, up to 100 mg (J3120)												
<i>With testosterone indications</i>												
2007	84	84	84	84	84	0.2	2,535,964	922,657.4	3.31	1.00	1.00	1.00
2008	157	157	157	157	157	0.4	4,947,402	1,711,948.8	3.17	1.00	1.00	1.00
2009	209	209	210	210	210	0.6	5,900,171	2,320,513.0	3.54	1.00	1.00	1.00
2010	290	290	290	290	290	0.8	5,821,555	2,289,762.0	4.98	1.00	1.00	1.00
2011	273	273	273	273	273	0.7	5,785,476	2,305,525.2	4.72	1.00	1.00	1.00
2012	286	286	286	286	286	0.8	5,716,216	2,284,954.7	5.00	1.00	1.00	1.00
2013	88	88	88	88	88	0.2	3,404,237	817,036.2	2.59	1.00	1.00	1.00
<i>Without testosterone indications</i>												
2007	182	182	182	182	182	0.5	23,500,888	17,214,504.3	0.77	1.00	1.00	1.00
2008	369	369	370	370	370	1.0	44,737,429	28,401,984.0	0.82	1.00	1.00	1.00
2009	480	480	481	481	481	1.3	46,608,794	36,456,704.1	1.03	1.00	1.00	1.00
2010	545	545	545	545	545	1.5	44,826,704	35,214,546.0	1.22	1.00	1.00	1.00
2011	519	519	519	519	519	1.4	43,656,741	34,642,099.7	1.19	1.00	1.00	1.00
2012	546	546	546	546	546	1.5	42,548,857	33,435,649.1	1.28	1.00	1.00	1.00
2013	156	156	156	156	156	0.4	32,972,286	11,962,058.4	0.47	1.00	1.00	1.00
Injection, testosterone enanthate, up to 200 mg (J3130)												
<i>With testosterone indications</i>												
2007	490	490	491	491	491	1.3	2,535,964	922,655.2	19.32	1.00	1.00	1.00
2008	713	713	713	713	713	2.0	4,947,262	1,711,902.8	14.41	1.00	1.00	1.00
2009	1,025	1,025	1,028	1,028	1,028	2.8	5,899,771	2,320,377.9	17.37	1.00	1.00	1.00
2010	1,012	1,012	1,013	1,013	1,013	2.8	5,820,913	2,289,534.6	17.39	1.00	1.00	1.00
2011	1,046	1,046	1,047	1,047	1,047	2.9	5,784,635	2,305,226.1	18.08	1.00	1.00	1.00
2012	1,200	1,200	1,202	1,202	1,202	3.3	5,715,228	2,284,572.0	21.00	1.00	1.00	1.00
2013	370	370	370	370	370	1.0	3,403,527	816,903.0	10.87	1.00	1.00	1.00
<i>Without testosterone indications</i>												
2007	1,200	1,200	1,201	1,201	1,201	3.3	23,500,888	17,214,478.2	5.11	1.00	1.00	1.00
2008	1,468	1,468	1,468	1,468	1,468	4.0	44,736,946	28,401,706.2	3.28	1.00	1.00	1.00
2009	1,798	1,798	1,803	1,803	1,803	4.9	46,607,666	36,455,991.0	3.86	1.00	1.00	1.00
2010	1,663	1,663	1,666	1,666	1,666	4.6	44,824,969	35,213,405.8	3.71	1.00	1.00	1.00
2011	1,745	1,745	1,746	1,746	1,746	4.8	43,654,699	34,640,660.3	4.00	1.00	1.00	1.00
2012	1,892	1,892	1,894	1,894	1,894	5.2	42,546,373	33,433,897.0	4.45	1.00	1.00	1.00
2013	611	611	611	611	611	1.7	32,970,068	11,961,387.5	1.85	1.00	1.00	1.00

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Injection, testosterone suspension, up to 50 mg (J3140)												
<i>With testosterone indications</i>												
2007	45	45	45	45	45	0.1	2,535,964	922,658.7	1.77	1.00	1.00	1.00
2008	94	94	94	94	94	0.3	4,947,415	1,711,954.2	1.90	1.00	1.00	1.00
2009	146	146	146	146	146	0.4	5,900,202	2,320,523.6	2.47	1.00	1.00	1.00
2010	165	165	167	167	167	0.5	5,821,593	2,289,779.5	2.83	1.01	1.01	1.00
2011	152	152	152	152	152	0.4	5,785,588	2,305,572.6	2.63	1.00	1.00	1.00
2012	154	154	154	154	154	0.4	5,716,359	2,285,016.7	2.69	1.00	1.00	1.00
2013	37	37	37	37	37	0.1	3,404,343	817,062.4	1.09	1.00	1.00	1.00
<i>Without testosterone indications</i>												
2007	114	114	114	114	114	0.3	23,500,888	17,214,505.3	0.49	1.00	1.00	1.00
2008	192	192	192	192	192	0.5	44,737,471	28,402,017.3	0.43	1.00	1.00	1.00
2009	302	302	302	302	302	0.8	46,608,922	36,456,785.0	0.65	1.00	1.00	1.00
2010	291	291	293	293	293	0.8	44,826,897	35,214,677.6	0.65	1.01	1.01	1.00
2011	266	266	266	266	266	0.7	43,657,098	34,642,338.2	0.61	1.00	1.00	1.00
2012	235	235	235	235	235	0.6	42,549,347	33,436,002.0	0.55	1.00	1.00	1.00
2013	71	71	71	71	71	0.2	32,972,753	11,962,215.3	0.22	1.00	1.00	1.00
Injection, testosterone propionate, up to 100 mg (J3150)												
<i>With testosterone indications</i>												
2007	45	45	45	45	45	0.1	2,535,964	922,659.0	1.77	1.00	1.00	1.00
2008	124	124	124	124	124	0.3	4,947,413	1,711,955.6	2.51	1.00	1.00	1.00
2009	175	175	175	175	175	0.5	5,900,188	2,320,524.4	2.97	1.00	1.00	1.00
2010	168	168	168	168	168	0.5	5,821,593	2,289,779.2	2.89	1.00	1.00	1.00
2011	199	199	199	199	199	0.5	5,785,575	2,305,577.2	3.44	1.00	1.00	1.00
2012	142	142	143	143	143	0.4	5,716,342	2,285,020.0	2.48	1.01	1.01	1.00
2013	50	50	50	50	50	0.1	3,404,360	817,066.4	1.47	1.00	1.00	1.00
<i>Without testosterone indications</i>												
2007	119	119	121	121	121	0.3	23,500,888	17,214,501.3	0.51	1.02	1.02	1.00
2008	251	251	251	251	251	0.7	44,737,456	28,402,004.7	0.56	1.00	1.00	1.00
2009	378	378	378	378	378	1.0	46,608,887	36,456,774.0	0.81	1.00	1.00	1.00
2010	314	314	314	314	314	0.9	44,826,818	35,214,643.5	0.70	1.00	1.00	1.00
2011	345	345	345	345	345	0.9	43,657,015	34,642,281.1	0.79	1.00	1.00	1.00
2012	298	298	299	299	299	0.8	42,549,201	33,435,919.4	0.70	1.00	1.00	1.00
2013	112	112	112	112	112	0.3	32,972,641	11,962,172.4	0.34	1.00	1.00	1.00
Testosterone pellet, 75mg (S0189)												
<i>With testosterone indications</i>												
2007	40	40	40	40	40	0.1	2,535,964	922,658.6	1.58	1.00	1.00	1.00
2008	142	142	142	142	142	0.4	4,947,421	1,711,956.6	2.87	1.00	1.00	1.00
2009	428	428	428	428	428	1.2	5,900,177	2,320,513.6	7.25	1.00	1.00	1.00
2010	734	734	736	736	736	2.0	5,821,423	2,289,704.2	12.61	1.00	1.00	1.00
2011	1,207	1,207	1,207	1,207	1,207	3.3	5,785,150	2,305,415.5	20.86	1.00	1.00	1.00
2012	1,896	1,896	1,896	1,896	1,896	5.2	5,715,509	2,284,724.0	33.17	1.00	1.00	1.00
2013	858	858	858	858	858	2.3	3,403,240	816,857.1	25.21	1.00	1.00	1.00
<i>Without testosterone indications</i>												
2007	122	122	122	122	122	0.3	23,500,888	17,214,503.2	0.52	1.00	1.00	1.00
2008	322	322	322	322	322	0.9	44,737,455	28,402,004.7	0.72	1.00	1.00	1.00
2009	719	719	719	719	719	2.0	46,608,807	36,456,714.0	1.54	1.00	1.00	1.00
2010	1,027	1,027	1,030	1,030	1,030	2.8	44,826,510	35,214,407.4	2.29	1.00	1.00	1.00
2011	1,550	1,550	1,550	1,550	1,550	4.2	43,656,342	34,641,846.6	3.55	1.00	1.00	1.00
2012	2,391	2,391	2,391	2,391	2,391	6.5	42,548,028	33,435,205.1	5.62	1.00	1.00	1.00
2013	1,060	1,060	1,060	1,060	1,060	2.9	32,970,908	11,961,711.1	3.21	1.00	1.00	1.00

Table 5. Summary of Incident Testosterone use in the MSDD between January 1, 2007 and May 31, 2013, by Testosterone Product, Pre-existing Conditions, Sex, and Age Group

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
All Testosterone Products												
<i>With testosterone indications</i>												
Female	13,804	13,804	14,625	221,859	417,487	605.0	10,851,997	8,247,670.7	127.20	16.07	1.06	15.17
0 to 39 Years	2,736	2,736	2,958	42,947	79,953		4,208,734	2,603,691	65.01	15.70	1.08	14.52
40 to 64 Years	10,174	10,174	10,732	164,758	318,339		5,167,785	3,982,345	196.87	16.19	1.05	15.35
65 to 74 Years	614	614	650	11,157	15,342		993,505	785,163	61.80	18.17	1.06	17.16
75+ Years	280	280	285	2,997	3,852		926,893	876,472	30.21	10.70	1.02	10.52
Male	317,403	317,403	455,494	13,096,902	44,162,082	35,508.4	6,634,389	4,340,216.6	4,784.21	41.26	1.44	28.75
0 to 39 Years	46,968	46,968	69,320	1,841,277	5,958,727		2,287,757	1,258,050	2,053.02	39.20	1.48	26.56
40 to 64 Years	225,823	225,823	327,503	9,417,905	32,975,302		3,263,866	2,109,374	6,918.88	41.70	1.45	28.76
65 to 74 Years	33,577	33,577	44,848	1,424,247	4,204,498		738,283	503,622	4,547.98	42.42	1.34	31.76
75+ Years	11,035	11,035	13,823	413,473	1,023,556		582,915	469,171	1,893.07	37.47	1.25	29.91
Unknown	95	95	137	3,608	12,415	9.8	5,448	3,521.7	1,743.76	37.98	1.44	26.34
0 to 39 Years	7	7	9	159	578		1,377	747	508.35	22.71	1.29	17.67
40 to 64 Years	73	73	109	2,967	10,318		2,928	2,014	2,493.17	40.64	1.49	27.22
65 to 74 Years	15	15	19	482	1,519		1,065	566	1,408.45	32.13	1.27	25.37
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	35,316	35,316	37,431	548,262	940,800	1,495.6	44,148,716	101,832,511.7	79.99	15.52	1.06	14.65
0 to 39 Years	7,328	7,328	7,960	114,387	173,214		25,591,113	51,106,686	28.63	15.61	1.09	14.37
40 to 64 Years	25,452	25,452	26,806	394,220	715,291		16,426,926	38,612,390	154.94	15.49	1.05	14.71
65 to 74 Years	1,703	1,703	1,805	30,866	42,062		2,904,846	6,648,263	58.63	18.12	1.06	17.10
75+ Years	833	833	860	8,789	10,232		1,858,636	5,465,173	44.82	10.55	1.03	10.22
Male	473,246	473,246	669,383	18,989,607	64,400,668	51,499.9	42,529,182	95,159,913.9	1,112.76	40.13	1.41	28.37
0 to 39 Years	68,620	68,620	98,310	2,573,729	8,054,308		25,329,381	50,326,450	270.91	37.51	1.43	26.18
40 to 64 Years	334,986	334,986	479,868	13,631,917	48,213,427		15,578,157	35,249,158	2,150.36	40.69	1.43	28.41
65 to 74 Years	52,407	52,407	69,756	2,166,047	6,557,833		2,667,376	5,835,882	1,964.74	41.33	1.33	31.05
75+ Years	17,233	17,233	21,449	617,914	1,575,099		1,370,561	3,748,424	1,257.37	35.86	1.24	28.81
Unknown	143	143	191	4,897	16,787	13.3	19,676	35,031.9	726.77	34.24	1.34	25.64
0 to 39 Years	15	15	17	324	613		7,276	11,285	206.16	21.60	1.13	19.06
40 to 64 Years	106	106	147	3,938	13,902		9,115	17,997	1,162.92	37.15	1.39	26.79
65 to 74 Years	20	20	25	633	2,270		3,566	4,566	560.85	31.65	1.25	25.32
75+ Years	2	2	2	2	2		733	1,184	272.85	1.00	1.00	1.00

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
AndroGel												
<i>With testosterone indications</i>												
Female	1,578	1,578	1,738	59,524	220,961	163.0	10,851,997	8,251,919.9	14.54	37.72	1.10	34.25
0 to 39 Years	263	263	320	10,110	40,488		4,208,734	2,604,258	6.25	38.44	1.22	31.59
40 to 64 Years	1,238	1,238	1,336	46,232	169,625		5,168,062	3,985,588	23.95	37.34	1.08	34.60
65 to 74 Years	60	60	64	2,492	8,418		993,590	785,425	6.04	41.53	1.07	38.94
75+ Years	17	17	18	690	2,430		926,939	876,650	1.83	40.59	1.06	38.33
Male	123,930	123,930	182,781	6,114,504	28,911,194	16,740.6	6,634,389	4,374,286.1	1,867.99	49.34	1.47	33.45
0 to 39 Years	16,881	16,881	25,441	789,938	3,837,622		2,287,757	1,261,364	737.88	46.79	1.51	31.05
40 to 64 Years	90,465	90,465	134,759	4,480,550	21,275,547		3,265,882	2,131,198	2,770.00	49.53	1.49	33.25
65 to 74 Years	12,980	12,980	17,925	669,940	3,045,950		740,637	509,276	1,752.55	51.61	1.38	37.37
75+ Years	3,604	3,604	4,656	174,076	752,076		584,213	472,449	616.90	48.30	1.29	37.39
Unknown	52	52	74	2,221	9,533	6.1	5,448	3,526.8	954.48	42.71	1.42	30.01
0 to 39 Years	3	3	4	107	535		1,377	747	217.86	35.67	1.33	26.75
40 to 64 Years	40	40	57	1,696	7,603		2,928	2,017	1,366.12	42.40	1.43	29.75
65 to 74 Years	9	9	13	418	1,395		1,067	567	843.49	46.44	1.44	32.15
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	3,764	3,764	4,172	144,067	520,112	394.4	44,148,716	101,868,278.0	8.53	38.27	1.11	34.53
0 to 39 Years	586	586	716	23,483	90,587		25,591,113	51,112,195	2.29	40.07	1.22	32.80
40 to 64 Years	2,959	2,959	3,221	111,446	399,483		16,428,059	38,638,944	18.01	37.66	1.09	34.60
65 to 74 Years	182	182	194	7,711	25,070		2,905,387	6,650,518	6.26	42.37	1.07	39.75
75+ Years	37	37	41	1,427	4,972		1,858,836	5,466,621	1.99	38.57	1.11	34.80
Male	188,293	188,293	275,101	9,224,860	43,885,163	25,256.3	42,529,182	95,312,839.1	442.74	48.99	1.46	33.53
0 to 39 Years	23,862	23,862	35,319	1,100,420	5,369,484		25,329,381	50,344,973	94.21	46.12	1.48	31.16
40 to 64 Years	138,050	138,050	203,809	6,788,006	32,418,942		15,582,650	35,345,805	885.92	49.17	1.48	33.31
65 to 74 Years	20,798	20,798	28,704	1,063,115	4,907,176		2,672,976	5,860,163	778.08	51.12	1.38	37.04
75+ Years	5,583	5,583	7,269	273,319	1,189,561		1,373,395	3,761,898	406.51	48.96	1.30	37.60
Unknown	75	75	104	3,130	13,143	8.6	19,676	35,056.5	381.18	41.73	1.39	30.10
0 to 39 Years	3	3	4	107	535		7,276	11,286	41.23	35.67	1.33	26.75
40 to 64 Years	59	59	81	2,425	10,463		9,115	18,017	647.28	41.10	1.37	29.94
65 to 74 Years	13	13	19	598	2,145		3,570	4,569	364.15	46.00	1.46	31.47
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Axiron												
With testosterone indications												
Female	28	28	32	1,124	2,880	3.1	10,851,997	8,252,533.3	0.26	40.14	1.14	35.13
0 to 39 Years	4	4	5	150	450		4,208,734	2,604,336	0.10	37.50	1.25	30.00
40 to 64 Years	23	23	26	944	2,340		5,168,086	3,986,087	0.45	41.04	1.13	36.31
65 to 74 Years	1	1	1	30	90		993,603	785,452	0.10	30.00	1.00	30.00
75+ Years	0	0	0	0	0		926,943	876,659	0.00	---	---	---
Male	8,219	8,219	10,486	318,963	1,005,154	873.3	6,634,389	4,396,398.9	123.88	38.81	1.28	30.42
0 to 39 Years	1,052	1,052	1,301	39,221	123,391		2,287,757	1,263,498	45.98	37.28	1.24	30.15
40 to 64 Years	6,606	6,606	8,521	258,108	815,089		3,267,266	2,146,528	202.19	39.07	1.29	30.29
65 to 74 Years	487	487	583	18,894	58,440		742,075	512,490	65.63	38.80	1.20	32.41
75+ Years	74	74	81	2,740	8,235		584,825	473,883	12.65	37.03	1.09	33.83
Unknown	4	4	4	120	360	0.3	5,448	3,531.7	73.42	30.00	1.00	30.00
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	3	3	3	90	270		2,928	2,021	102.46	30.00	1.00	30.00
65 to 74 Years	1	1	1	30	90		1,070	569	93.46	30.00	1.00	30.00
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
Without testosterone indications												
Female	46	46	50	1,746	4,753	4.8	44,148,716	101,873,075.0	0.10	37.96	1.09	34.92
0 to 39 Years	6	6	7	198	594		25,591,113	51,112,732	0.02	33.00	1.17	28.29
40 to 64 Years	38	38	41	1,396	3,703		16,428,179	38,642,824	0.23	36.74	1.08	34.05
65 to 74 Years	1	1	1	30	90		2,905,464	6,650,822	0.03	30.00	1.00	30.00
75+ Years	1	1	1	122	366		1,858,854	5,466,698	0.05	122.00	1.00	122.00
Male	11,176	11,176	14,119	430,560	1,352,987	1,178.8	42,529,182	95,420,458.4	26.28	38.53	1.26	30.50
0 to 39 Years	1,361	1,361	1,670	50,159	157,027		25,329,381	50,355,121	5.37	36.85	1.23	30.04
40 to 64 Years	8,990	8,990	11,470	348,798	1,098,809		15,585,860	35,421,699	57.68	38.80	1.28	30.41
65 to 74 Years	694	694	833	26,513	81,949		2,676,819	5,875,566	25.93	38.20	1.20	31.83
75+ Years	131	131	146	5,090	15,202		1,374,984	3,768,072	9.53	38.85	1.11	34.86
Unknown	5	5	5	150	450	0.4	19,676	35,082.1	25.41	30.00	1.00	30.00
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	4	4	4	120	360		9,115	18,037	43.88	30.00	1.00	30.00
65 to 74 Years	1	1	1	30	90		3,578	4,575	27.95	30.00	1.00	30.00
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Fortesta												
<i>With testosterone indications</i>												
Female	28	28	28	920	1,650	2.5	10,851,997	8,252,529.1	0.26	32.86	1.00	32.86
0 to 39 Years	1	1	1	90	60		4,208,734	2,604,336	0.02	90.00	1.00	90.00
40 to 64 Years	27	27	27	830	1,590		5,168,086	3,986,082	0.52	30.74	1.00	30.74
65 to 74 Years	0	0	0	0	0		993,603	785,452	0.00	---	---	---
75+ Years	0	0	0	0	0		926,943	876,659	0.00	---	---	---
Male	4,118	4,118	5,530	164,546	350,534	450.5	6,634,389	4,396,553.1	62.07	39.96	1.34	29.76
0 to 39 Years	609	609	791	22,892	48,445		2,287,757	1,263,515	26.62	37.59	1.30	28.94
40 to 64 Years	3,269	3,269	4,425	131,591	281,097		3,267,279	2,146,637	100.05	40.25	1.35	29.74
65 to 74 Years	212	212	273	8,710	18,296		742,090	512,512	28.57	41.08	1.29	31.90
75+ Years	28	28	41	1,353	2,696		584,825	473,889	4.79	48.32	1.46	33.00
Unknown	2	2	3	90	180	0.2	5,448	3,531.3	36.71	45.00	1.50	30.00
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	2	2	3	90	180		2,928	2,021	68.31	45.00	1.50	30.00
65 to 74 Years	0	0	0	0	0		1,070	569	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	53	53	54	1,675	3,220	4.6	44,148,716	101,873,062.3	0.12	31.60	1.02	31.02
0 to 39 Years	4	4	5	210	360		25,591,113	51,112,733	0.02	52.50	1.25	42.00
40 to 64 Years	49	49	49	1,465	2,860		16,428,179	38,642,809	0.30	29.90	1.00	29.90
65 to 74 Years	0	0	0	0	0		2,905,464	6,650,822	0.00	---	---	---
75+ Years	0	0	0	0	0		1,858,854	5,466,698	0.00	---	---	---
Male	5,605	5,605	7,429	222,550	472,266	609.3	42,529,182	95,420,846.4	13.18	39.71	1.33	29.96
0 to 39 Years	791	791	1,026	29,973	63,859		25,329,381	50,355,154	3.12	37.89	1.30	29.21
40 to 64 Years	4,471	4,471	5,962	178,015	378,765		15,585,900	35,421,985	28.69	39.82	1.33	29.86
65 to 74 Years	296	296	378	12,339	25,505		2,676,847	5,875,621	11.06	41.69	1.28	32.64
75+ Years	47	47	63	2,223	4,136		1,374,987	3,768,086	3.42	47.30	1.34	35.29
Unknown	2	2	3	90	180	0.2	19,676	35,082.3	10.16	45.00	1.50	30.00
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	2	2	3	90	180		9,115	18,037	21.94	45.00	1.50	30.00
65 to 74 Years	0	0	0	0	0		3,578	4,575	0.00	---	---	---
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Methyltestosterone												
<i>With testosterone indications</i>												
Female	506	506	671	33,636	16,534	92.1	10,851,997	8,252,346.4	4.66	66.47	1.33	50.13
0 to 39 Years	77	77	108	4,447	2,219		4,208,734	2,604,320	1.83	57.75	1.40	41.18
40 to 64 Years	390	390	507	26,565	12,615		5,168,077	3,985,936	7.55	68.12	1.30	52.40
65 to 74 Years	37	37	52	2,506	1,516		993,596	785,439	3.72	67.73	1.41	48.19
75+ Years	2	2	4	118	184		926,940	876,652	0.22	59.00	2.00	29.50
Male	781	781	1,419	48,909	79,286	133.9	6,634,389	4,396,555.4	11.77	62.62	1.82	34.47
0 to 39 Years	113	113	188	5,828	8,847		2,287,757	1,263,525	4.94	51.58	1.66	31.00
40 to 64 Years	573	573	1,075	36,720	61,797		3,267,284	2,146,665	17.54	64.08	1.88	34.16
65 to 74 Years	64	64	112	4,796	6,720		742,090	512,489	8.62	74.94	1.75	42.82
75+ Years	31	31	44	1,565	1,922		584,827	473,876	5.30	50.48	1.42	35.57
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		2,928	2,021	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		1,070	569	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	1,500	1,500	1,981	97,669	49,685	267.4	44,148,716	101,870,651.2	3.40	65.11	1.32	49.30
0 to 39 Years	234	234	298	12,368	7,015		25,591,113	51,112,468	0.91	52.85	1.27	41.50
40 to 64 Years	1,150	1,150	1,495	74,570	37,038		16,428,121	38,640,960	7.00	64.84	1.30	49.88
65 to 74 Years	106	106	159	8,644	4,785		2,905,410	6,650,584	3.65	81.55	1.50	54.36
75+ Years	10	10	29	2,087	847		1,858,836	5,466,639	0.54	208.70	2.90	71.97
Male	1,518	1,518	2,567	90,186	141,281	246.9	42,529,182	95,420,264.4	3.57	59.41	1.69	35.13
0 to 39 Years	201	201	324	9,817	15,106		25,329,381	50,355,119	0.79	48.84	1.61	30.30
40 to 64 Years	1,104	1,104	1,871	64,703	104,553		15,585,905	35,421,711	7.08	58.61	1.69	34.58
65 to 74 Years	155	155	286	12,247	17,437		2,676,843	5,875,430	5.79	79.01	1.85	42.82
75+ Years	58	58	86	3,419	4,185		1,374,978	3,768,004	4.22	58.95	1.48	39.76
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		9,115	18,038	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		3,578	4,575	0.00	---	---	---
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---
Striant												
<i>With testosterone indications</i>												
Female	10	10	10	347	339	1.0	10,851,997	8,252,531.7	0.09	34.70	1.00	34.70
0 to 39 Years	2	2	2	51	51		4,208,734	2,604,335	0.05	25.50	1.00	25.50
40 to 64 Years	6	6	6	236	218		5,168,085	3,986,086	0.12	39.33	1.00	39.33
65 to 74 Years	2	2	2	60	70		993,603	785,452	0.20	30.00	1.00	30.00
75+ Years	0	0	0	0	0		926,943	876,659	0.00	---	---	---

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Male	405	405	510	17,652	33,891	48.3	6,634,389	4,396,693.4	6.10	43.59	1.26	34.61
0 to 39 Years	79	79	92	2,985	5,898		2,287,757	1,263,537	3.45	37.78	1.16	32.45
40 to 64 Years	285	285	362	12,027	23,133		3,267,297	2,146,754	8.72	42.20	1.27	33.22
65 to 74 Years	31	31	34	1,350	2,580		742,097	512,513	4.18	43.55	1.10	39.71
75+ Years	10	10	22	1,290	2,280		584,829	473,890	1.71	129.00	2.20	58.64
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		2,928	2,021	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		1,070	569	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
Without testosterone indications												
Female	26	26	26	872	662	2.4	44,148,716	101,873,046.4	0.06	33.54	1.00	33.54
0 to 39 Years	5	5	5	141	126		25,591,113	51,112,730	0.02	28.20	1.00	28.20
40 to 64 Years	19	19	19	671	446		16,428,177	38,642,798	0.12	35.32	1.00	35.32
65 to 74 Years	2	2	2	60	90		2,905,463	6,650,820	0.07	30.00	1.00	30.00
75+ Years	0	0	0	0	0		1,858,854	5,466,698	0.00	---	---	---
Male	633	633	770	26,220	50,058	71.8	42,529,182	95,421,256.3	1.49	41.42	1.22	34.05
0 to 39 Years	112	112	144	4,478	8,834		25,329,381	50,355,227	0.44	39.98	1.29	31.10
40 to 64 Years	449	449	533	17,652	33,839		15,585,931	35,422,328	2.88	39.31	1.19	33.12
65 to 74 Years	57	57	65	2,460	4,635		2,676,874	5,875,615	2.13	43.16	1.14	37.85
75+ Years	15	15	28	1,630	2,750		1,374,992	3,768,085	1.09	108.67	1.87	58.21
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		9,115	18,038	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		3,578	4,575	0.00	---	---	---
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---
Intramuscular Testosterone Other												
With testosterone indications												
Female	137	137	143	5,110	1,494	14.0	10,851,997	8,252,488.8	1.26	37.30	1.04	35.73
0 to 39 Years	29	29	30	1,185	210		4,208,734	2,604,331	0.69	40.86	1.03	39.50
40 to 64 Years	101	101	106	3,720	1,099		5,168,083	3,986,052	1.95	36.83	1.05	35.09
65 to 74 Years	4	4	4	110	35		993,602	785,451	0.40	27.50	1.00	27.50
75+ Years	3	3	3	95	150		926,942	876,655	0.32	31.67	1.00	31.67
Male	4,494	4,494	5,374	214,930	30,941	588.4	6,634,389	4,395,922.8	67.74	47.83	1.20	39.99
0 to 39 Years	938	938	1,120	38,709	6,075		2,287,757	1,263,401	41.00	41.27	1.19	34.56
40 to 64 Years	2,844	2,844	3,410	132,971	20,022		3,267,254	2,146,310	87.05	46.75	1.20	38.99
65 to 74 Years	514	514	605	31,162	3,545		742,051	512,406	69.27	60.63	1.18	51.51
75+ Years	198	198	239	12,088	1,298		584,791	473,805	33.86	61.05	1.21	50.58

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		2,928	2,021	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		1,070	569	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
Without testosterone indications												
Female	352	352	370	12,971	4,174	35.5	44,148,716	101,872,662.0	0.80	36.85	1.05	35.06
0 to 39 Years	90	90	97	3,520	751		25,591,113	51,112,673	0.35	39.11	1.08	36.29
40 to 64 Years	240	240	250	8,688	2,964		16,428,164	38,642,501	1.46	36.20	1.04	34.75
65 to 74 Years	15	15	16	557	235		2,905,457	6,650,806	0.52	37.13	1.07	34.81
75+ Years	7	7	7	206	224		1,858,852	5,466,681	0.38	29.43	1.00	29.43
Male	7,405	7,405	8,736	345,153	60,448	945.0	42,529,182	95,417,450.3	17.41	46.61	1.18	39.51
0 to 39 Years	2,025	2,025	2,334	82,310	12,481		25,329,381	50,353,779	7.99	40.65	1.15	35.27
40 to 64 Years	4,317	4,317	5,160	199,980	40,909		15,585,826	35,420,672	27.70	46.32	1.20	38.76
65 to 74 Years	778	778	903	45,886	5,241		2,676,755	5,875,175	29.07	58.98	1.16	50.82
75+ Years	285	285	339	16,977	1,818		1,374,920	3,767,825	20.73	59.57	1.19	50.08
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		9,115	18,038	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		3,578	4,575	0.00	---	---	---
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---
Testosterone Cypionate												
With testosterone indications												
Female	1,687	1,687	1,832	71,446	21,363	195.6	10,851,997	8,251,995.4	15.55	42.35	1.09	39.00
0 to 39 Years	385	385	450	16,059	3,805		4,208,734	2,604,265	9.15	41.71	1.17	35.69
40 to 64 Years	1,179	1,179	1,247	48,804	16,319		5,168,054	3,985,675	22.81	41.39	1.06	39.14
65 to 74 Years	85	85	95	4,774	987		993,589	785,415	8.55	56.16	1.12	50.25
75+ Years	38	38	40	1,809	252		926,935	876,641	4.10	47.61	1.05	45.23
Male	56,818	56,818	84,188	3,189,831	474,265	8,733.3	6,634,389	4,388,177.0	856.42	56.14	1.48	37.89
0 to 39 Years	9,632	9,632	15,123	511,382	82,909		2,287,757	1,262,674	421.02	53.09	1.57	33.81
40 to 64 Years	37,965	37,965	56,495	2,060,798	314,565		3,266,766	2,141,396	1,162.16	54.28	1.49	36.48
65 to 74 Years	6,809	6,809	9,355	456,991	56,917		741,510	511,046	918.26	67.12	1.37	48.85
75+ Years	2,412	2,412	3,215	160,660	19,875		584,459	473,061	412.69	66.61	1.33	49.97
Unknown	11	11	12	400	46	1.1	5,448	3,531.7	201.91	36.36	1.09	33.33
0 to 39 Years	1	1	1	30	16		1,377	747	72.62	30.00	1.00	30.00
40 to 64 Years	10	10	11	370	30		2,928	2,021	341.53	37.00	1.10	33.64
65 to 74 Years	0	0	0	0	0		1,070	569	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Without testosterone indications												
Female	4,564	4,564	5,060	193,292	53,747	529.2	44,148,716	101,868,508.7	10.34	42.35	1.11	38.20
0 to 39 Years	1,195	1,195	1,474	53,769	10,931		25,591,113	51,112,140	4.67	44.99	1.23	36.48
40 to 64 Years	3,067	3,067	3,265	124,422	38,854		16,428,056	38,639,304	18.67	40.57	1.06	38.11
65 to 74 Years	211	211	228	10,981	2,712		2,905,374	6,650,505	7.26	52.04	1.08	48.16
75+ Years	91	91	93	4,120	1,250		1,858,833	5,466,560	4.90	45.27	1.02	44.30
Male	82,755	82,755	120,641	4,593,582	693,966	12,576.5	42,529,182	95,388,567.1	194.58	55.51	1.46	38.08
0 to 39 Years	14,555	14,555	21,865	755,160	125,715		25,329,381	50,350,500	57.46	51.88	1.50	34.54
40 to 64 Years	54,633	54,633	80,276	2,934,730	454,347		15,584,748	35,402,341	350.55	53.72	1.47	36.56
65 to 74 Years	10,084	10,084	13,856	672,226	85,227		2,675,622	5,870,490	376.88	66.66	1.37	48.52
75+ Years	3,483	3,483	4,644	231,466	28,676		1,374,242	3,765,237	253.45	66.46	1.33	49.84
Unknown	17	17	18	710	106	1.9	19,676	35,082.8	86.40	41.76	1.06	39.44
0 to 39 Years	4	4	4	190	46		7,276	11,286	54.98	47.50	1.00	47.50
40 to 64 Years	13	13	14	520	60		9,115	18,038	142.62	40.00	1.08	37.14
65 to 74 Years	0	0	0	0	0		3,578	4,575	0.00	---	---	---
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---
Transdermal Testosterone												
With testosterone indications												
Female	201	201	224	7,110	7,867	19.5	10,851,997	8,252,467.9	1.85	35.37	1.11	31.74
0 to 39 Years	62	62	65	1,519	1,966		4,208,734	2,604,330	1.47	24.50	1.05	23.37
40 to 64 Years	135	135	155	5,473	5,807		5,168,080	3,986,030	2.61	40.54	1.15	35.31
65 to 74 Years	4	4	4	118	94		993,602	785,450	0.40	29.50	1.00	29.50
75+ Years	0	0	0	0	0		926,941	876,658	0.00	---	---	---
Male	18,301	18,301	25,637	890,906	942,254	2,439.2	6,634,389	4,392,732.3	275.85	48.68	1.40	34.75
0 to 39 Years	2,497	2,497	3,445	111,636	118,064		2,287,757	1,263,176	109.15	44.71	1.38	32.41
40 to 64 Years	13,291	13,291	18,599	641,403	678,778		3,267,113	2,144,107	406.81	48.26	1.40	34.49
65 to 74 Years	1,839	1,839	2,663	101,472	107,451		741,824	511,859	247.90	55.18	1.45	38.10
75+ Years	674	674	930	36,395	37,961		584,703	473,590	115.27	54.00	1.38	39.13
Unknown	5	5	6	210	210	0.6	5,448	3,530.1	91.78	42.00	1.20	35.00
0 to 39 Years	1	1	1	30	30		1,377	747	72.62	30.00	1.00	30.00
40 to 64 Years	3	3	4	150	150		2,928	2,021	102.46	50.00	1.33	37.50
65 to 74 Years	1	1	1	30	30		1,069	568	93.55	30.00	1.00	30.00
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Without testosterone indications												
Female	709	709	762	18,926	19,582	51.8	44,148,716	101,872,301.1	1.61	26.69	1.07	24.84
0 to 39 Years	262	262	276	4,683	4,928		25,591,113	51,112,580	1.02	17.87	1.05	16.97
40 to 64 Years	429	429	464	13,361	13,707		16,428,128	38,642,237	2.61	31.14	1.08	28.80
65 to 74 Years	16	16	19	791	827		2,905,455	6,650,795	0.55	49.44	1.19	41.63
75+ Years	2	2	3	91	120		1,858,851	5,466,689	0.11	45.50	1.50	30.33
Male	28,948	28,948	40,561	1,420,734	1,502,380	3,889.8	42,529,182	95,400,641.8	68.07	49.08	1.40	35.03
0 to 39 Years	3,711	3,711	5,170	167,799	178,159		25,329,381	50,353,468	14.65	45.22	1.39	32.46
40 to 64 Years	21,018	21,018	29,386	1,019,962	1,079,113		15,585,415	35,408,349	134.86	48.53	1.40	34.71
65 to 74 Years	3,078	3,078	4,458	172,276	182,122		2,676,032	5,872,262	115.02	55.97	1.45	38.64
75+ Years	1,141	1,141	1,547	60,697	62,987		1,374,673	3,766,563	83.00	53.20	1.36	39.24
Unknown	6	6	7	240	270	0.7	19,676	35,072.8	30.49	40.00	1.17	34.29
0 to 39 Years	1	1	1	30	30		7,276	11,286	13.74	30.00	1.00	30.00
40 to 64 Years	4	4	5	180	210		9,115	18,030	43.88	45.00	1.25	36.00
65 to 74 Years	1	1	1	30	30		3,576	4,572	27.96	30.00	1.00	30.00
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---
Testim												
With testosterone indications												
Female	1,074	1,074	1,130	35,459	134,633	97.1	10,851,997	8,252,154.0	9.90	33.02	1.05	31.38
0 to 39 Years	220	220	224	7,080	27,293		4,208,734	2,604,288	5.23	32.18	1.02	31.61
40 to 64 Years	822	822	872	27,411	102,585		5,168,063	3,985,777	15.91	33.35	1.06	31.43
65 to 74 Years	27	27	29	784	3,975		993,593	785,435	2.72	29.04	1.07	27.03
75+ Years	5	5	5	184	780		926,940	876,654	0.54	36.80	1.00	36.80
Male	45,700	45,700	70,953	2,324,619	12,544,899	6,364.5	6,634,389	4,389,401.5	688.84	50.87	1.55	32.76
0 to 39 Years	6,422	6,422	9,934	306,379	1,663,146		2,287,757	1,262,888	280.71	47.71	1.55	30.84
40 to 64 Years	34,938	34,938	54,797	1,796,171	9,714,199		3,266,812	2,141,674	1,069.48	51.41	1.57	32.78
65 to 74 Years	3,500	3,500	5,092	180,573	954,667		741,579	511,414	471.97	51.59	1.45	35.46
75+ Years	840	840	1,130	41,496	212,886		584,622	473,425	143.68	49.40	1.35	36.72
Unknown	7	7	13	376	2,060	1.0	5,448	3,529.2	128.49	53.71	1.86	28.92
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	7	7	13	376	2,060		2,928	2,019	239.07	53.71	1.86	28.92
65 to 74 Years	0	0	0	0	0		1,069	568	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
Without testosterone indications												
Female	2,121	2,121	2,221	70,149	273,348	192.1	44,148,716	101,870,692.2	4.80	33.07	1.05	31.58
0 to 39 Years	404	404	422	12,904	52,669		25,591,113	51,112,412	1.58	31.94	1.04	30.58
40 to 64 Years	1,641	1,641	1,720	54,900	210,268		16,428,085	38,640,908	9.99	33.46	1.05	31.92
65 to 74 Years	63	63	66	1,872	8,435		2,905,425	6,650,705	2.17	29.71	1.05	28.36
75+ Years	13	13	13	473	1,975		1,858,848	5,466,667	0.70	36.38	1.00	36.38

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Male	63,930	63,930	98,386	3,235,851	17,357,048	8,859.3	42,529,182	95,390,128.5	150.32	50.62	1.54	32.89
0 to 39 Years	8,345	8,345	12,732	394,652	2,138,326		25,329,381	50,352,414	32.95	47.29	1.53	31.00
40 to 64 Years	49,010	49,010	76,259	2,507,581	13,479,273		15,584,915	35,400,419	314.47	51.16	1.56	32.88
65 to 74 Years	5,284	5,284	7,656	270,973	1,418,665		2,675,640	5,870,979	197.49	51.28	1.45	35.39
75+ Years	1,291	1,291	1,739	62,645	320,784		1,374,566	3,766,317	93.92	48.52	1.35	36.02
Unknown	11	11	17	519	3,075	1.4	19,676	35,077.2	55.91	47.18	1.55	30.53
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	10	10	16	489	2,925		9,115	18,033	109.71	48.90	1.60	30.56
65 to 74 Years	1	1	1	30	150		3,577	4,574	27.96	30.00	1.00	30.00
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---
Testopel												
<i>With testosterone indications</i>												
Female	4	4	4	120	213	0.3	10,851,997	8,252,527.4	0.04	30.00	1.00	30.00
0 to 39 Years	1	1	1	30	90		4,208,734	2,604,336	0.02	30.00	1.00	30.00
40 to 64 Years	3	3	3	90	123		5,168,086	3,986,081	0.06	30.00	1.00	30.00
65 to 74 Years	0	0	0	0	0		993,603	785,452	0.00	---	---	---
75+ Years	0	0	0	0	0		926,943	876,659	0.00	---	---	---
Male	470	470	474	15,602	6,188	42.7	6,634,389	4,396,627.0	7.08	33.20	1.01	32.92
0 to 39 Years	66	66	66	2,030	901		2,287,757	1,263,535	2.88	30.76	1.00	30.76
40 to 64 Years	349	349	353	10,971	4,676		3,267,281	2,146,693	10.68	31.44	1.01	31.08
65 to 74 Years	44	44	44	2,260	499		742,100	512,508	5.93	51.36	1.00	51.36
75+ Years	11	11	11	341	112		584,828	473,891	1.88	31.00	1.00	31.00
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		2,928	2,021	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		1,070	569	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	5	5	5	121	214	0.3	44,148,716	101,873,070.9	0.01	24.20	1.00	24.20
0 to 39 Years	1	1	1	30	90		25,591,113	51,112,732	0.00	30.00	1.00	30.00
40 to 64 Years	4	4	4	91	124		16,428,179	38,642,819	0.02	22.75	1.00	22.75
65 to 74 Years	0	0	0	0	0		2,905,464	6,650,822	0.00	---	---	---
75+ Years	0	0	0	0	0		1,858,854	5,466,698	0.00	---	---	---

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Male	532	532	539	18,302	6,981	50.1	42,529,182	95,421,416.4	1.25	34.40	1.01	33.96
0 to 39 Years	70	70	70	2,191	939		25,329,381	50,355,253	0.28	31.30	1.00	31.30
40 to 64 Years	394	394	400	12,522	5,215		15,585,922	35,422,424	2.53	31.78	1.02	31.31
65 to 74 Years	53	53	54	2,828	675		2,676,888	5,875,647	1.98	53.36	1.02	52.37
75+ Years	15	15	15	761	152		1,374,993	3,768,092	1.09	50.73	1.00	50.73
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		9,115	18,038	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		3,578	4,575	0.00	---	---	---
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---
Injection, testosterone cypionate, up to 100 mg (J1070)												
<i>With testosterone indications</i>												
Female	4,254	4,254	4,256	4,256	4,256	11.7	10,851,997	8,251,072.0	39.20	1.00	1.00	1.00
0 to 39 Years	898	898	898	898	898		4,208,734	2,604,106	21.34	1.00	1.00	1.00
40 to 64 Years	3,099	3,099	3,101	3,101	3,101		5,167,975	3,984,991	59.97	1.00	1.00	1.00
65 to 74 Years	174	174	174	174	174		993,574	785,372	17.51	1.00	1.00	1.00
75+ Years	83	83	83	83	83		926,931	876,603	8.95	1.00	1.00	1.00
Male	11,635	11,635	11,646	11,646	11,646	31.9	6,634,389	4,394,398.0	175.37	1.00	1.00	1.00
0 to 39 Years	2,016	2,016	2,020	2,020	2,020		2,287,757	1,263,299	88.12	1.00	1.00	1.00
40 to 64 Years	7,653	7,653	7,658	7,658	7,658		3,267,162	2,145,373	234.24	1.00	1.00	1.00
65 to 74 Years	1,403	1,403	1,405	1,405	1,405		741,962	512,110	189.09	1.00	1.00	1.00
75+ Years	563	563	563	563	563		584,725	473,617	96.28	1.00	1.00	1.00
Unknown	2	2	2	2	2	0.0	5,448	3,531.7	36.71	1.00	1.00	1.00
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	2	2	2	2	2		2,928	2,021	68.31	1.00	1.00	1.00
65 to 74 Years	0	0	0	0	0		1,070	569	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	11,427	11,427	11,431	11,431	11,431	31.3	44,148,716	101,859,955.2	25.88	1.00	1.00	1.00
0 to 39 Years	2,492	2,492	2,493	2,493	2,493		25,591,113	51,110,398	9.74	1.00	1.00	1.00
40 to 64 Years	8,180	8,180	8,183	8,183	8,183		16,427,721	38,633,212	49.79	1.00	1.00	1.00
65 to 74 Years	497	497	497	497	497		2,905,277	6,650,130	17.11	1.00	1.00	1.00
75+ Years	258	258	258	258	258		1,858,788	5,466,214	13.88	1.00	1.00	1.00

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Male	19,685	19,685	19,702	19,702	19,702	53.9	42,529,182	95,409,268.3	46.29	1.00	1.00	1.00
0 to 39 Years	3,527	3,527	3,532	3,532	3,532		25,329,381	50,353,395	13.92	1.00	1.00	1.00
40 to 64 Years	12,728	12,728	12,737	12,737	12,737		15,585,604	35,415,397	81.67	1.00	1.00	1.00
65 to 74 Years	2,418	2,418	2,420	2,420	2,420		2,676,532	5,873,710	90.34	1.00	1.00	1.00
75+ Years	1,012	1,012	1,013	1,013	1,013		1,374,754	3,766,767	73.61	1.00	1.00	1.00
Unknown	5	5	5	5	5	0.0	19,676	35,079.2	25.41	1.00	1.00	1.00
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	5	5	5	5	5		9,115	18,035	54.85	1.00	1.00	1.00
65 to 74 Years	0	0	0	0	0		3,577	4,574	0.00	---	---	---
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---
Injection, testosterone cypionate, 1 cc, 200 mg (J1080)												
<i>With testosterone indications</i>												
Female	2,743	2,743	2,749	2,749	2,749	7.5	10,851,997	8,251,490.9	25.28	1.00	1.00	1.00
0 to 39 Years	565	565	566	566	566		4,208,734	2,604,205	13.42	1.00	1.00	1.00
40 to 64 Years	1,904	1,904	1,909	1,909	1,909		5,168,029	3,985,324	36.84	1.00	1.00	1.00
65 to 74 Years	164	164	164	164	164		993,588	785,374	16.51	1.00	1.00	1.00
75+ Years	110	110	110	110	110		926,928	876,589	11.87	1.00	1.00	1.00
Male	51,176	51,176	51,236	51,236	51,236	140.3	6,634,389	4,386,928.3	771.37	1.00	1.00	1.00
0 to 39 Years	7,805	7,805	7,817	7,817	7,817		2,287,757	1,262,578	341.16	1.00	1.00	1.00
40 to 64 Years	33,839	33,839	33,878	33,878	33,878		3,266,725	2,140,826	1,035.87	1.00	1.00	1.00
65 to 74 Years	6,690	6,690	6,697	6,697	6,697		741,436	510,849	902.30	1.00	1.00	1.00
75+ Years	2,842	2,842	2,844	2,844	2,844		584,385	472,676	486.32	1.00	1.00	1.00
Unknown	10	10	10	10	10	0.0	5,448	3,531.7	183.55	1.00	1.00	1.00
0 to 39 Years	2	2	2	2	2		1,377	747	145.24	1.00	1.00	1.00
40 to 64 Years	5	5	5	5	5		2,928	2,021	170.77	1.00	1.00	1.00
65 to 74 Years	3	3	3	3	3		1,070	569	280.37	1.00	1.00	1.00
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	7,590	7,590	7,596	7,596	7,596	20.8	44,148,716	101,864,402.1	17.19	1.00	1.00	1.00
0 to 39 Years	1,612	1,612	1,613	1,613	1,613		25,591,113	51,111,334	6.30	1.00	1.00	1.00
40 to 64 Years	5,097	5,097	5,102	5,102	5,102		16,427,932	38,636,816	31.03	1.00	1.00	1.00
65 to 74 Years	515	515	515	515	515		2,905,353	6,650,159	17.73	1.00	1.00	1.00
75+ Years	366	366	366	366	366		1,858,779	5,466,093	19.69	1.00	1.00	1.00

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Male	84,206	84,206	84,304	84,304	84,304	230.8	42,529,182	95,374,497.6	198.00	1.00	1.00	1.00
0 to 39 Years	12,364	12,364	12,383	12,383	12,383		25,329,381	50,350,274	48.81	1.00	1.00	1.00
40 to 64 Years	55,901	55,901	55,966	55,966	55,966		15,584,606	35,393,737	358.69	1.00	1.00	1.00
65 to 74 Years	11,167	11,167	11,178	11,178	11,178		2,675,273	5,867,675	417.42	1.00	1.00	1.00
75+ Years	4,774	4,774	4,777	4,777	4,777		1,373,972	3,762,812	347.46	1.00	1.00	1.00
Unknown	22	22	22	22	22	0.1	19,676	35,078.4	111.81	1.00	1.00	1.00
0 to 39 Years	7	7	7	7	7		7,276	11,285	96.21	1.00	1.00	1.00
40 to 64 Years	10	10	10	10	10		9,115	18,035	109.71	1.00	1.00	1.00
65 to 74 Years	3	3	3	3	3		3,578	4,575	83.85	1.00	1.00	1.00
75+ Years	2	2	2	2	2		733	1,184	272.85	1.00	1.00	1.00
Injection, testosterone enanthate, up to 100 mg (J3120)												
<i>With testosterone indications</i>												
Female	219	219	219	219	219	0.6	10,851,997	8,252,456.6	2.02	1.00	1.00	1.00
0 to 39 Years	43	43	43	43	43		4,208,734	2,604,327	1.02	1.00	1.00	1.00
40 to 64 Years	153	153	153	153	153		5,168,081	3,986,031	2.96	1.00	1.00	1.00
65 to 74 Years	12	12	12	12	12		993,600	785,447	1.21	1.00	1.00	1.00
75+ Years	11	11	11	11	11		926,940	876,652	1.19	1.00	1.00	1.00
Male	1,167	1,167	1,168	1,168	1,168	3.2	6,634,389	4,396,409.5	17.59	1.00	1.00	1.00
0 to 39 Years	179	179	179	179	179		2,287,757	1,263,510	7.82	1.00	1.00	1.00
40 to 64 Years	730	730	731	731	731		3,267,287	2,146,610	22.34	1.00	1.00	1.00
65 to 74 Years	176	176	176	176	176		742,088	512,444	23.72	1.00	1.00	1.00
75+ Years	82	82	82	82	82		584,816	473,846	14.02	1.00	1.00	1.00
Unknown	1	1	1	1	1	0.0	5,448	3,531.3	18.36	1.00	1.00	1.00
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	1	1	1	1	1		2,928	2,021	34.15	1.00	1.00	1.00
65 to 74 Years	0	0	0	0	0		1,070	569	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	587	587	587	587	587	1.6	44,148,716	101,872,475.9	1.33	1.00	1.00	1.00
0 to 39 Years	101	101	101	101	101		25,591,113	51,112,649	0.39	1.00	1.00	1.00
40 to 64 Years	422	422	422	422	422		16,428,163	38,642,409	2.57	1.00	1.00	1.00
65 to 74 Years	42	42	42	42	42		2,905,458	6,650,777	1.45	1.00	1.00	1.00
75+ Years	22	22	22	22	22		1,858,844	5,466,641	1.18	1.00	1.00	1.00
Male	2,209	2,209	2,211	2,211	2,211	6.1	42,529,182	95,419,987.2	5.19	1.00	1.00	1.00
0 to 39 Years	467	467	468	468	468		25,329,381	50,354,905	1.84	1.00	1.00	1.00
40 to 64 Years	1,277	1,277	1,278	1,278	1,278		15,585,904	35,421,815	8.19	1.00	1.00	1.00
65 to 74 Years	316	316	316	316	316		2,676,844	5,875,375	11.80	1.00	1.00	1.00
75+ Years	149	149	149	149	149		1,374,970	3,767,893	10.84	1.00	1.00	1.00

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Unknown	1	1	1	1	1	0.0	19,676	35,082.4	5.08	1.00	1.00	1.00
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	1	1	1	1	1		9,115	18,038	10.97	1.00	1.00	1.00
65 to 74 Years	0	0	0	0	0		3,578	4,575	0.00	---	---	---
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---
Injection, testosterone enanthate, up to 200 mg (J3130)												
<i>With testosterone indications</i>												
Female	226	226	226	226	226	0.6	10,851,997	8,252,437.0	2.08	1.00	1.00	1.00
0 to 39 Years	39	39	39	39	39		4,208,734	2,604,324	0.93	1.00	1.00	1.00
40 to 64 Years	160	160	160	160	160		5,168,080	3,986,027	3.10	1.00	1.00	1.00
65 to 74 Years	16	16	16	16	16		993,601	785,435	1.61	1.00	1.00	1.00
75+ Years	11	11	11	11	11		926,942	876,650	1.19	1.00	1.00	1.00
Male	5,628	5,628	5,636	5,636	5,636	15.4	6,634,389	4,395,202.9	84.83	1.00	1.00	1.00
0 to 39 Years	776	776	776	776	776		2,287,757	1,263,423	33.92	1.00	1.00	1.00
40 to 64 Years	3,698	3,698	3,705	3,705	3,705		3,267,239	2,145,905	113.18	1.00	1.00	1.00
65 to 74 Years	774	774	774	774	774		741,982	512,196	104.32	1.00	1.00	1.00
75+ Years	380	380	381	381	381		584,759	473,679	64.98	1.00	1.00	1.00
Unknown	2	2	2	2	2	0.0	5,448	3,531.7	36.71	1.00	1.00	1.00
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	1	1	1	1	1		2,928	2,021	34.15	1.00	1.00	1.00
65 to 74 Years	1	1	1	1	1		1,070	569	93.46	1.00	1.00	1.00
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	641	641	641	641	641	1.8	44,148,716	101,872,309.0	1.45	1.00	1.00	1.00
0 to 39 Years	127	127	127	127	127		25,591,113	51,112,591	0.50	1.00	1.00	1.00
40 to 64 Years	449	449	449	449	449		16,428,151	38,642,315	2.73	1.00	1.00	1.00
65 to 74 Years	43	43	43	43	43		2,905,449	6,650,738	1.48	1.00	1.00	1.00
75+ Years	22	22	22	22	22		1,858,851	5,466,665	1.18	1.00	1.00	1.00
Male	9,732	9,732	9,744	9,744	9,744	26.7	42,529,182	95,414,135.4	22.88	1.00	1.00	1.00
0 to 39 Years	1,330	1,330	1,330	1,330	1,330		25,329,381	50,354,452	5.25	1.00	1.00	1.00
40 to 64 Years	6,327	6,327	6,337	6,337	6,337		15,585,796	35,418,217	40.59	1.00	1.00	1.00
65 to 74 Years	1,384	1,384	1,384	1,384	1,384		2,676,599	5,874,316	51.71	1.00	1.00	1.00
75+ Years	691	691	693	693	693		1,374,808	3,767,151	50.26	1.00	1.00	1.00
Unknown	4	4	4	4	4	0.0	19,676	35,081.7	20.33	1.00	1.00	1.00
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	2	2	2	2	2		9,115	18,037	21.94	1.00	1.00	1.00
65 to 74 Years	2	2	2	2	2		3,578	4,575	55.90	1.00	1.00	1.00
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Injection, testosterone suspension, up to 50 mg (J3140)												
<i>With testosterone indications</i>												
Female	134	134	134	134	134	0.4	10,851,997	8,252,469.9	1.23	1.00	1.00	1.00
0 to 39 Years	30	30	30	30	30		4,208,734	2,604,322	0.71	1.00	1.00	1.00
40 to 64 Years	95	95	95	95	95		5,168,083	3,986,045	1.84	1.00	1.00	1.00
65 to 74 Years	6	6	6	6	6		993,603	785,447	0.60	1.00	1.00	1.00
75+ Years	3	3	3	3	3		926,943	876,655	0.32	1.00	1.00	1.00
Male	659	659	661	661	661	1.8	6,634,389	4,396,566.0	9.93	1.00	1.00	1.00
0 to 39 Years	121	121	121	121	121		2,287,757	1,263,523	5.29	1.00	1.00	1.00
40 to 64 Years	439	439	440	440	440		3,267,289	2,146,677	13.44	1.00	1.00	1.00
65 to 74 Years	63	63	64	64	64		742,096	512,494	8.49	1.02	1.02	1.00
75+ Years	36	36	36	36	36		584,826	473,873	6.16	1.00	1.00	1.00
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		2,928	2,021	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		1,070	569	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
<i>Without testosterone indications</i>												
Female	332	332	332	332	332	0.9	44,148,716	101,872,636.3	0.75	1.00	1.00	1.00
0 to 39 Years	69	69	69	69	69		25,591,113	51,112,653	0.27	1.00	1.00	1.00
40 to 64 Years	239	239	239	239	239		16,428,168	38,642,532	1.45	1.00	1.00	1.00
65 to 74 Years	16	16	16	16	16		2,905,460	6,650,782	0.55	1.00	1.00	1.00
75+ Years	8	8	8	8	8		1,858,852	5,466,669	0.43	1.00	1.00	1.00
Male	1,139	1,139	1,141	1,141	1,141	3.1	42,529,182	95,420,821.6	2.68	1.00	1.00	1.00
0 to 39 Years	217	217	217	217	217		25,329,381	50,355,116	0.86	1.00	1.00	1.00
40 to 64 Years	751	751	752	752	752		15,585,918	35,422,130	4.82	1.00	1.00	1.00
65 to 74 Years	106	106	107	107	107		2,676,869	5,875,573	3.96	1.01	1.01	1.00
75+ Years	65	65	65	65	65		1,374,983	3,768,003	4.73	1.00	1.00	1.00
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		9,115	18,038	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		3,578	4,575	0.00	---	---	---
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---
Injection, testosterone propionate, up to 100 mg (J3150)												
<i>With testosterone indications</i>												
Female	245	245	245	245	245	0.7	10,851,997	8,252,450.2	2.26	1.00	1.00	1.00
0 to 39 Years	40	40	40	40	40		4,208,734	2,604,326	0.95	1.00	1.00	1.00
40 to 64 Years	196	196	196	196	196		5,168,078	3,986,018	3.79	1.00	1.00	1.00
65 to 74 Years	6	6	6	6	6		993,603	785,451	0.60	1.00	1.00	1.00

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
75+ Years	3	3	3	3	3		926,943	876,656	0.32	1.00	1.00	1.00
Male	658	658	659	659	659	1.8	6,634,389	4,396,599.9	9.92	1.00	1.00	1.00
0 to 39 Years	104	104	104	104	104		2,287,757	1,263,523	4.55	1.00	1.00	1.00
40 to 64 Years	437	437	438	438	438		3,267,289	2,146,703	13.38	1.00	1.00	1.00
65 to 74 Years	78	78	78	78	78		742,096	512,498	10.51	1.00	1.00	1.00
75+ Years	39	39	39	39	39		584,823	473,876	6.67	1.00	1.00	1.00
Unknown	0	0	0	0	0	0.0	5,448	3,531.7	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		2,928	2,021	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		1,070	569	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
Without testosterone indications												
Female	698	698	699	699	699	1.9	44,148,716	101,872,392.6	1.58	1.00	1.00	1.00
0 to 39 Years	95	95	96	96	96		25,591,113	51,112,652	0.37	1.01	1.01	1.00
40 to 64 Years	571	571	571	571	571		16,428,158	38,642,241	3.48	1.00	1.00	1.00
65 to 74 Years	24	24	24	24	24		2,905,454	6,650,809	0.83	1.00	1.00	1.00
75+ Years	8	8	8	8	8		1,858,854	5,466,691	0.43	1.00	1.00	1.00
Male	1,119	1,119	1,121	1,121	1,121	3.1	42,529,182	95,420,821.0	2.63	1.00	1.00	1.00
0 to 39 Years	146	146	146	146	146		25,329,381	50,355,190	0.58	1.00	1.00	1.00
40 to 64 Years	745	745	747	747	747		15,585,923	35,422,091	4.78	1.00	1.00	1.00
65 to 74 Years	154	154	154	154	154		2,676,864	5,875,545	5.75	1.00	1.00	1.00
75+ Years	74	74	74	74	74		1,374,973	3,767,995	5.38	1.00	1.00	1.00
Unknown	0	0	0	0	0	0.0	19,676	35,082.8	0.00	---	---	---
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	0	0	0	0	0		9,115	18,038	0.00	---	---	---
65 to 74 Years	0	0	0	0	0		3,578	4,575	0.00	---	---	---
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---
Testosterone pellet, 75mg (S0189)												
With testosterone indications												
Female	1,112	1,112	1,112	1,112	1,112	3.0	10,851,997	8,252,248.5	10.25	1.00	1.00	1.00
0 to 39 Years	127	127	127	127	127		4,208,734	2,604,318	3.02	1.00	1.00	1.00
40 to 64 Years	959	959	959	959	959		5,168,068	3,985,828	18.56	1.00	1.00	1.00
65 to 74 Years	25	25	25	25	25		993,599	785,444	2.52	1.00	1.00	1.00
75+ Years	1	1	1	1	1		926,943	876,659	0.11	1.00	1.00	1.00
Male	4,192	4,192	4,194	4,194	4,194	11.5	6,634,389	4,396,049.6	63.19	1.00	1.00	1.00
0 to 39 Years	473	473	474	474	474		2,287,757	1,263,486	20.68	1.00	1.00	1.00
40 to 64 Years	3,381	3,381	3,382	3,382	3,382		3,267,259	2,146,239	103.48	1.00	1.00	1.00
65 to 74 Years	295	295	295	295	295		742,058	512,445	39.75	1.00	1.00	1.00
75+ Years	43	43	43	43	43		584,821	473,880	7.35	1.00	1.00	1.00

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 100K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Unknown	1	1	1	1	1	0.0	5,448	3,531.5	18.36	1.00	1.00	1.00
0 to 39 Years	0	0	0	0	0		1,377	747	0.00	---	---	---
40 to 64 Years	1	1	1	1	1		2,928	2,021	34.15	1.00	1.00	1.00
65 to 74 Years	0	0	0	0	0		1,070	569	0.00	---	---	---
75+ Years	0	0	0	0	0		311	195	0.00	---	---	---
Without testosterone indications												
Female	2,383	2,383	2,384	2,384	2,384	6.5	44,148,716	101,871,177.8	5.40	1.00	1.00	1.00
0 to 39 Years	228	228	228	228	228		25,591,113	51,112,631	0.89	1.00	1.00	1.00
40 to 64 Years	2,103	2,103	2,104	2,104	2,104		16,428,140	38,641,094	12.80	1.00	1.00	1.00
65 to 74 Years	48	48	48	48	48		2,905,434	6,650,760	1.65	1.00	1.00	1.00
75+ Years	4	4	4	4	4		1,858,852	5,466,692	0.22	1.00	1.00	1.00
Male	4,807	4,807	4,809	4,809	4,809	13.2	42,529,182	95,420,131.8	11.30	1.00	1.00	1.00
0 to 39 Years	550	550	551	551	551		25,329,381	50,355,140	2.17	1.00	1.00	1.00
40 to 64 Years	3,872	3,872	3,873	3,873	3,873		15,585,882	35,421,414	24.84	1.00	1.00	1.00
65 to 74 Years	338	338	338	338	338		2,676,822	5,875,512	12.63	1.00	1.00	1.00
75+ Years	47	47	47	47	47		1,374,978	3,768,066	3.42	1.00	1.00	1.00
Unknown	1	1	1	1	1	0.0	19,676	35,082.6	5.08	1.00	1.00	1.00
0 to 39 Years	0	0	0	0	0		7,276	11,286	0.00	---	---	---
40 to 64 Years	1	1	1	1	1		9,115	18,038	10.97	1.00	1.00	1.00
65 to 74 Years	0	0	0	0	0		3,578	4,575	0.00	---	---	---
75+ Years	0	0	0	0	0		733	1,184	0.00	---	---	---

Appendix A. List of ICD-9 Diagnosis Codes for Pre-existing Condition Criteria Included in this Request

Description	Diagnosis Code
Malignant neoplasm of pituitary gland and craniopharyngeal duct	194.3*
Benign neoplasm of pituitary gland and craniopharyngeal duct	227.3*
Other anterior pituitary disorders	253.4*
Klinefelter's syndrome	758.7*
Other testicular hypofunction	257.2*
Depressive disorder, not elsewhere classified	311*
Muscular wasting and disuse atrophy, not elsewhere classified	728.2*
Other malaise and fatigue	780.79
Decreased libido	799.81
Hypoactive sexual desire disorder	302.71
Other testicular dysfunction	257.8*
Unspecified testicular dysfunction	257.9*

signifies "starts with." For example, 194.3 will consider 194.3, 194.30, 194.31, 194.32, and so on.